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1 Introduction 
Glioblastoma (GBM; World Health Organization (WHO) grade IV glioma) remains one of 
the tumour types most difficult to treat as multiple genetic lesions promote therapy re-
sistance, complemented by severe destructive infiltration of the surrounding brain (Brennan 
et al., 2013; Weller et al., 2015; Louis et al., 2016). Despite advances in our understanding 
of genetics and molecular mechanisms underlying GBM development and progression, pa-
tients with GBM still have a poor prognosis with an estimated five year overall survival of 
less than five percent (McLendon et al., 2008; Stupp et al., 2009). The standard treatment 
consists of surgery followed by radiotherapy and chemotherapy using the DNA-methylating 
agent Temozolomide (TMZ) (Stupp et al., 2009; Becker and Yu, 2012). While resistance to 
therapy has been mainly attributed to inter- and intratumoural heterogeneity as well as 
stemness (Stupp et al., 2014; Fidoamore et al., 2016; Wei et al., 2016), increasing evidence 
points at the importance of cell-extracellular matrix (ECM) interactions as a further essential 
mechanism (Tabatabai et al., 2011; Eke et al., 2012; Vehlow and Cordes, 2013; Eke et al., 
2015; Fidoamore et al., 2016; Vehlow et al., 2017). 
Cell-ECM interactions are mainly but not exclusively facilitated by the integrin family 
of cell adhesion molecules (Tabatabai et al., 2011; Seguin et al., 2015). It is generally ac-
cepted that cell adhesion molecules fundamentally impact on cancer cell therapy resistance 
as they convey survival- and invasion-promoting microenvironmental cues in GBM as well 
as numerous other cancers (Cordes and Meineke, 2003; Cabodi et al., 2010; Desgrosellier 
and Cheresh, 2010; Eke et al., 2010; Nam et al., 2010; Eke et al., 2012; Eke and Cordes, 
2014; Dickreuter et al., 2016; Vehlow et al., 2017). Despite these promising data from pre-
clinical cancer models, integrin targeting agents have demonstrated low efficacy in clinical 
trials (www.clinicaltrials.org). In GBM, the αvβ3/β5 integrin-antagonist Cilengitide failed to 
improve patient outcome in a phase III clinical trial (Stupp et al., 2014). 
In search of other potential resistance-mediating ECM receptors, type I collagen (Col 
I) was shown to populate microenvironmental niches where GBM stem cells (GSC) reside, 
survive treatment and propagate into recurrence (Motegi et al., 2014; Gao et al., 2016). 
Similar to integrins, the receptor tyrosine kinase Discoidin Domain Receptor 1 (DDR1) binds 
to and is activated by collagens, however a direct link to therapy resistance has not been 
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established (Vogel et al., 1997; Leitinger, 2014). In GBM, elevated DDR1 mRNA expression 
potentially correlates with poor prognosis, advanced tumor stage, invasiveness and stem-
ness (Weiner et al., 2000; Ram et al., 2006; Yamanaka et al., 2006; Rennert et al., 2016). 
This renders DDR1 a potential therapeutic target as part of the current multimodal treatment 
for GBM including radiotherapy and Temozolomide. 
In addition to mitotic cell death and apoptosis, which were thought to present the major 
cell death modes in solid tumors upon radiochemotherapy, autophagy receives increasing 
attention. Autophagy is an evolutionary conserved self-digestion program that fundamen-
tally contributes to the regulation of cellular homeostasis and metabolism (Levine and 
Kroemer, 2008; Fulda and Kögel, 2015). Under physiological conditions, autophagy is part 
of the cellular stress response for ensuring cell survival under unfavorable conditions such 
as starvation (Levine and Kroemer, 2008; Fulda and Kögel, 2015). Cancer cells, however, 
were shown to frequently hijack this prosurvival function of autophagy to resist therapeutic 
challenge (Gozuacik and Kimchi, 2004; Codogno and Meijer, 2005). Consequently, inter-
ference with autophagy might be therapeutically exploitable rendering cancer cells more 
susceptible to treatment (Holohan et al., 2013; Galluzzi et al., 2016). 
In the present study, we explored the as yet unknown functions of DDR1 in GBM cell 
survival and therapy resistance and uncovered its contributing molecular mechanism. We 
found that co-expression of DDR1 with GBM stem cell markers in clinical samples correlates 
with patient outcome and DDR1 inhibition induces autophagy, enhances sensitivity and pro-
longs survival in response to radiochemotherapy with Temozolomide. Mechanistically, a 14-
3-3/Beclin-1/Akt1 protein complex assembles with DDR1 and is required for prosurvival 
Akt/mTOR signaling and regulation of autophagy. 
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2 Background 
2.1 Glioblastoma 
2.1.1 Epidemiology 
Glioblastoma (GBM), intrinsic tumours of the brain, belong to the group of diseases for 
which there is currently no cure (Westphal and Lamszus, 2015). Despite continuous re-
search on the molecular mechanisms of GBM development, progression and therapy 
resistance during the past decades, only very limited progress has been made towards 
controlling the disease course. Still, these tumours are associated with a poor prognosis 
and rare long-term survival of patients (McLendon et al., 2008; Stupp et al., 2009; Cancer 
Genome Atlas Research Network et al., 2015). GBM account for 80 % of all brain tu-
mours and 30 % of the primary ones (Weller et al., 2015). In Germany, cancers of the 
central nervous system (CNS) make up 1.4 to 1.6 % of newly diagnosed cancers (Figure 
2.1) with a 5-year overall survival rate of 21 to 22 % (Kaatsch et al., 2015). In 2012, more 
than 7200 new cases of CNS cancers were diagnosed in Germany. These comprise 
about 4000 cases in men and 3200 diagnosed CNS cancers in women (Kaatsch et al., 
2015). In general, the incidence of CNS tumours increases with age ranging from less 
than 5 per 100,000 in children and young adults (0 to 34 years) to more than 15 per 
100,000 in people aged 65 to 75 years and more than 25 per 100,000 in individuals aging 
75 or more (Figure 2.1 and Kaatsch et al., 2015). The biological basis for increased GBM 
risk with advanced age has, to date, not been elucidated. Moreover, compared to fe-
males, males report a higher incidence and mortality that is independent of age. GBM 
predominantly manifests in patients >50 years of age (Ostrom, Gittleman et al., 2014) 
with men being diagnosed on average at 63 years and women at 66 years (Kaatsch et 
al., 2015). 
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Glioblastomas belong to the group of astrocytic brain tumours. Histologically, the 
absence or presence of anaplastic features is used to assign malignancy grades from 
WHO grade I to IV, with WHO grade I indicating the least malignant behaviour. In adults, 
common astrocytic tumours include diffuse astrocytoma (WHO grade II), anaplastic as-
trocytoma (WHO grade III) and glioblastoma (WHO grade IV) (Kleihues et al., 2002; 
Louis et al., 2007) with GBM accounting for the most common and the most aggressive 
primary brain tumour. It is characterised by the hallmark features of necrosis, microvas-
cular proliferation, very high cell density, anaplasia, high mitotic rates, resistance to 
apoptosis, genomic instability and invasiveness (Furnari et al., 2007; Louis et al., 2007; 
Weller et al., 2015; Wirsching et al., 2016). Glioblastomas mostly occur de novo (primary 
Figure 2.1. Frequency and age-related morbidity of brain and CNS cancers in Germany. (a) Overview 
of the frequencies of different cancer entities of patients with newly diagnosed cancer and (b) age-related 
morbidity of brain and CNS cancers according to the 10th “Krebs in Deutschland” report of the Robert Koch 
Institut (Kaatsch et al., 2015). 
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GBM, 90 %), but can evolve from a preceding low grade astrocytoma (secondary GBM) 
manifesting predominantly in younger patients (Furnari et al., 2007; Weller et al., 2015).  
For many decades, histological classification was applied as the ‘gold standard’ for 
GBM diagnostics. Given that for most CNS tumours the WHO grade serves as rough 
estimate of malignancy and histological grading is associated with considerable interob-
server variability, integration of molecular GBM classifiers promise a more precise cor-
relation with clinical outcome than sole histological classification (Kleihues et al., 2002; 
Reifenberger et al., 2016). Hence, in the revised 2016 WHO “Classification of Tumours 
of the CNS” recent improvements of the understanding of molecular signalling pathways 
and GBM genetics lead to the incorporation of histological and molecular information of 
CNS tumours into a novel, multifaceted disease categorisation (Louis et al., 2016; 
Reifenberger et al., 2016). 
2.1.2 Molecular characteristics 
In order to complement the histology-based classification for optimised and personalised 
GBM therapy, great efforts have been undertaken to characterise GBM on the molecular 
level. Numerous studies provide evidence that primary glioblastomas typically show 
EGFR amplification (40 % of cases) and/or overexpression (60 %), PTEN mutations 
(30 %), p16INK4a deletion (30-40 %), MDM2 amplification (10 %) and/or overexpression 
(50%) and loss of heterozygosity on chromosome 10 (50-80 % of cases). In contrast, 
secondary glioblastomas develop more slowly by malignant progression from low grade 
astrocytomas (WHO grade II-III) and are characterised by mutations of the tumour sup-
pressor TP53 in approximately 60% of cases as well as allelic loss of chromosomes 19q 
and 10q (Kleihues et al., 2002; Furnari et al., 2007).  
Moreover, recent large-scale profiling studies defined distinct genetic subgroups 
that correlate with patient survival (Phillips et al., 2006; McLendon et al., 2008; Verhaak 
et al., 2010; Sturm et al., 2012). One subgroup, associated with improved outcome, is 
characterised by an IDH mutation along with a CpG island mutator phenotype (g-CIMP). 
According to the classification system introduced by The Cancer Genome Atlas (TCGA) 
consortium (Verhaak et al., 2010) this GBM subtype resembles a proneural mRNA ex-
pression profile. The IDH-mutant GBM subtype accounts for less than 10% of all glio-
blastomas, commonly occurs in young adults and includes almost all secondary GBM 
(Sturm et al., 2012; Weller et al., 2015; Reifenberger et al., 2016). In line, this group 
shows the highest enrichment for TP53 mutations (Sturm et al., 2012). Among the IDH-
wild-type GBM subgroups three distinct clusters have been defined. The “receptor 
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tyrosine kinase I” (RTK I) subgroup is characterised by PDGFRA amplification and a 
proneural gene-expression profile (Sturm et al., 2012). While RTK I glioblastomas pre-
dominantly manifest in adolescents and young adults, the “receptor tyrosine kinase II” 
(RTK II) and the “mesenchymal” IDH-wild-type GBM subtypes typically occur in patients 
>50 years of age (Weller et al., 2015). The RTK II subgroup demonstrates a high fre-
quency of whole chromosome 7 gain and whole chromosome 10 loss, as well as homo-
zygous deletion of CDKN2A, amplification of EGFR and expression of the constitutively 
active EGFR variant III (EGFRvIII) (Sturm et al., 2012). Moreover, the RTK II group re-
sembles the mRNA-expression profile of the classical GBM subtype. The majority of gli-
oblastomas is assigned to this subgroup (Ostrom, Bauchet et al., 2014), which is further 
characterised by high expression of FGFR3, AKT2 and the neural precursor marker NES 
(Verhaak et al., 2010). The mesenchymal cluster is foremost demonstrating loss of NF1 
and PTEN and expression of mesenchymal markers like CHI3L1 and MET (Verhaak et 
al., 2010).  
Collectively, these genetic alterations in GBM trigger aberrant activation of several 
tumour-promoting pathways, including Ras-MAPK and PI3K/AKT/mTOR signalling and 
induced telomerase activity via TERT activation (Furnari et al., 2007). On the other hand, 
important tumour-suppressive pathways are impaired. Here, especially regulation of 
apoptosis and cell cycle progression through the TP53 and RB1 pathway are disrupted 
(Weller et al., 2015). Another important feature of GBM pathogenesis is rapid tumour 
growth leading to tissue hypoxia. Reduced oxygen levels not only cause necrosis, but 
also induce aberrant angiogenesis via upregulation of HIF1α and VEGF. Moreover, the 
influence of the tumour on the patient’s immune system, including suppression of an 
effective antitumour immune response, for example via upregulation of TGFβ, is of im-
portance (Weller et al., 2015).  
Together, these developments have markedly improved the mechanistic under-
standing of GBM tumorigenesis and have identified novel biomarkers that are hoped to 
improve tumour classification and patient outcome (Louis et al., 2016). 
 
2.1.3 GBM therapy 
Despite vast improvements in the understanding of molecular mechanisms underlying 
glioblastomagenesis as well as extensive attempts to categorise GBM subtypes accord-
ing to their genetic features and predicted outcome, the targeting of identified glioma 
drivers like EGFR, mTOR signalling and angiogenesis (by the αvβ3/β5 integrin-
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antagonist Cilengitide) has not proven effective in randomised controlled trials 
(Cloughesy et al., 2008; Stupp et al., 2014; Wen et al., 2014). Hence, a multimodal treat-
ment regimen of surgery followed by radio- and chemotherapy using the DNA-alkylating 
agent Temozolomide (TMZ) is still the standard of care for GBM patients (Stupp et al., 
2009; Becker and Yu, 2012).  
Complete resection is prognostically favourable, but only possible if the tumour 
shows a circumscribed growth (Weller et al., 2015). While low grade CNS cancers such 
as pilocytic astrocytoma or subependymal giant-cell astrocytoma are characterised by 
such a growth pattern, glioblastomas commonly shown pronounced destructive invasion 
of the brain and dissemination within the CNS (Westphal and Lamszus, 2011). Even 
though surgeons nowadays make use of intraoperative imaging by ultrasound or MRI to 
achieve optimal resection, diffuse gliomas generally recur after surgery (Wirsching et al., 
2016). Therefore, additional treatment aimed at a prolongation of patient survival while 
maintaining quality of life is necessary. 
Postsurgical radiotherapy provides improved local tumour control in patients with 
diffuse glioblastomas when compared with surgery alone and prolongs patient survival 
(Reifenberger et al., 2016). Typically, 60 Gy X-rays in 30 fractions are administered 
within 6 weeks (2 Gy fractions, 5 days/week) concomitantly with 42 days of daily chem-
otherapy with 75 mg/m2 TMZ. This regimen is followed by 6 to 12 cycles of 150-
200 mg/m2 TMZ given every 5 days of a 28-day cycle (Figure 2.2 and Becker and Yu, 
2012). 
As DNA-alkylating chemotherapeutic agent, TMZ induces DNA-adducts. A major 
TMZ-induced DNA-adduct, 6-O-methylguanine, is effectively repaired by the DNA me-
thyltransferase MGMT. First, MGMT itself becomes alkylated followed by ubiquitinylation 
and subsequent proteasomal degradation. Methylation of the MGMT-promoter has been 
closely linked to prolonged survival of GBM patients due to beneficial effects of the radi-
otherapy/TMZ treatment (Hegi et al., 2005). Moreover, phase III trials in GBM patients 
aged more than 65 years revealed that MGMT-promoter methylation is a highly 
Figure 2.2. Treatment regimen for patients with newly diagnosed GBM. According to the treatment 
protocol established by Stupp et al. (Stupp et al., 2005; Stupp et al., 2009) GBM patients receive gross total 
tumour resection followed by concomitant TMZ treatment plus X-ray irradiation for 6 weeks. After a treatment 
stop of 4 weeks, 200 mg/m2 TMZ are administered adjuvantly for 5 days on a 28-day cycle. 
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prognostic biomarker for guiding treatment decisions since patients with active MGMT 
do not benefit from TMZ concomitantly administered to radiotherapy (Stupp et al., 2005; 
Stupp et al., 2009). 
Despite extensive treatment, glioblastomas almost always recurr due to incomplete 
resection and/or development of resistance to therapy. To date, only a few options for 
treatment of GBM recurrences exist. Gross total resection does prolong overall survival 
durations in patients with recurrent glioblastoma (Suchorska et al., 2016). Radiotherapy 
at recurrence is an option for patients without first-line radiotherapy due to neurotoxic 
dose accumulation and radionecrosis. TMZ can be used at disease recurrence but has 
been shown to have only moderate effects. A forth option is antiangiogenic therapy with 
the VEGF inhibitor bevacizumab, which was approved in the USA for the treatment of 
recurrent GBM (Reifenberger et al., 2016). Taken together, due to extensive invasion of 
GBM cells into the surrounding normal brain and high intrinsic treatment resistance, ef-
fective treatment options to cure GBM patients are lacking. These facts point at the ur-
gent need for the development of novel treatment strategies combining targeting agents 
to the conventional treatment modalities for maximal therapeutic effectiveness.  
 
2.2 Physical and biological action of ionizing radiation 
The treatment of tumours with ionizing radiation is one main pillar of clinical oncology. 
To date, 50-60 % of all cancers are treated with irradiation (Begg et al., 2011; Moding et 
al., 2013). While different types of ionizing radiation like electrons, α-particles, protons or 
heavy ions as well as X- and γ-rays may be applied for therapeutic purposes, X-ray irra-
diation is used most often (Hall and Giaccia, 2012). Already two years after their discov-
ery by Wilhelm Conrad Röntgen in 1895, X-rays were used to treat tumours (Walsh, 
1897) and typical side-effects like erythema and ulcerations have been described (Hall 
and Giaccia, 2012).  
In general, two distinct types of irradiation, particulate irradiations (electrons, neu-
trons, α-particles, protons or heavy ions) and electromagnetic irradiations (X- and γ-rays) 
can be distinguished. Moreover, radiations may be classified as directly or indirectly ion-
ising. With regard to direct ionisations, charged particles hit an electron in the outer shell 
of an atom and eject it by the help of its electric field. Within this process a secondary 
electron and an ion (= charged atom) are produced. These direct ionisations can be 
generated by electrons or photons. On the opposite, electromagnetic radiations, like X-
rays, are indirectly ionising. During the process of indirect ionisation an X-ray photon is 
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absorbed by the target material and a part of the photon’s energy is given to a “free” 
electron as kinetic energy. The vacancy is filled either by an electron from an outer orbit 
or by a free electron from outside the atom and characteristic X-rays are released 
(Herrmann et al., 1997; Hall and Giaccia, 2012).  
The relative biological effectiveness of a particular radiation is dependent on the 
density of ionising events along a defined track and on the amount of deposited energy. 
The density of ionising events can be calculated by the help of the linear energy transfer 
(LET). The LET reflects the average amount of energy that is deposited by charged par-
ticles along a defined track length in the target material and is given as kilo-electron volts 
(keV) per µm. The LET is dependent on the type of charged particle and its energy. 
Hence, ionising radiations with high LET (= densely ionizing) and low LET (= sparsely 
ionising) are differentiated. The relative biological effectiveness, importantly, increases 
with the LET. X-rays, that are typically used for therapeutic purposes, are sparsely ion-
ising radiations with a comparatively low LET of >3.5 keV/µm. The absorbed dose is 
defined as the amount of energy emitted by a charged particle that is transferred to a 
defined unit of mass. The unit of the dose is Gray (Gy) and is calculated by dividing the 
absorbed energy by the mass of a given object (1 Gy = 1 J/kg). In radiotherapy, this unit 
is used to describe the dose that is given to a patient (Herrmann et al., 1997; Hall and 
Giaccia, 2012; Kavanagh et al., 2013).  
The main target of ionising radiation in cells is the DNA, where it induces DNA 
damages like single or double strand breaks (Steel, 2002; Hall and Giaccia, 2012). If the 
cell is not able to repair the damage, cell proliferation is hampered mostly due to lethal 
chromosomal aberrations and mutations. Here, the LET as a representative of the den-
sity of ionising events along a given track is the key determinant for the amount of DNA 
damage induced by a certain type of radiation. Consequently, the amount of DNA dam-
age induced by radiation is an indicator of its biological effectiveness. 
Irradiation may induce DNA lesions either directly or indirectly. If damage in the 
DNA is caused directly by a secondary electron, the ionisation and the biological effect 
happen directly at the target molecule. If damage is elicited via various molecules that 
are involved in the ionising event at the target site, this process is defined as indirectly 
ionising. In mammalian cells, typically water molecules transmit the effect of radiation to 
the DNA as water is the most abundant cellular molecule. Irradiation causes hydrolysis 
of the water molecules subsequently generating free radical associated DNA damage 
(Figure 2.3). For X-rays, indirect effects account for 70 % of the induced damage 
(Herrmann et al., 1997; Hall and Giaccia, 2012; Kavanagh et al., 2013).  
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2.3 Therapy resistance 
Surgery, radio- and chemotherapy are the integral components of cancer care and are 
commonly employed locally (surgery and radiotherapy) and systemically (chemotherapy) 
to eradicate tumour cells with either curative or palliative intent (Arruebo et al., 2011; 
Baskar et al., 2014; Kerr, 2016). Despite many technical improvements and optimisation 
of treatment regimens, radio- and chemotherapy often fail to achieve local tumour con-
trol. As simple delivery of higher doses alone is not sufficient to solve this issue, due to 
an inacceptable increase of cytotoxicity and adverse side-effects, there is a demand on 
novel treatment options to overcome therapy resistance (Higgins et al., 2015; Rammal 
et al., 2016).  
The mechanisms of therapy resistance can be defined by the terms intrinsic and 
acquired resistance (Holohan et al., 2013). Intrinsic resistance indicates that resistance-
mediating factors pre-exist in the bulk of tumour cells prior to therapy application render-
ing the therapy ineffective. In this context, molecular and genetic tumour heterogeneity 
is of major importance as small tumour cell subpopulations, intrinsically resistant against 
the applied therapy, can be selected under the course of treatment. Cells of a selected 
subset may possess stem-cell qualities and are thus able to regrow the tumour for 
Figure 2.3. Direct and indirect DNA damage induced by ionising radiation. Direct DNA damage is in-
duced if a photon is absorbed by an atom to produce a secondary electron. This secondary electron may 
directly interact with the DNA (direct DNA damage) or with a water molecule. Interaction of the secondary 
electron with a water molecule results in hydrolysis and production of free radicals, which finally induce DNA 
damage (indirect DNA damage) (Hall and Giaccia, 2012). 
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relapse (Holohan et al., 2013). Cancer stem cell populations have many properties that 
separate them from the actively dividing bulk-tumour cells like the ability to self-renew 
and to differentiate as well as a high capacity for DNA repair and a high proportion of 
quiescent cells in the G0 phase (Schlag et al., 2007). Thus, conventional radiochemo-
therapy alone is unlikely to eradicate all cancer stem cells as those therapies are directed 
against highly proliferative cells.  
In this context, the recent development of targeted anticancer drugs, specifically 
blocking mutated or overexpressed proteins involved in cancer development and pro-
gression, has led to great optimism that these substances may enable sustained thera-
peutic control of many types of cancer. However, by applying targeting agents in clinical 
trials it became apparent that only few if any cures can be achieved by these drugs 
(Garraway and Jänne, 2012). Soon after the first introduction of molecular targeting ap-
proaches it was recognised that after an initial treatment response patients experience 
disease progression caused by therapy resistance of a certain subset of tumour cells, 
finally leading to treatment failure and death from recurrent or metastatic disease (Klemm 
and Joyce, 2014).  
These data point at another mechanism of resistance that is developed during 
treatment of tumours that were initially sensitive, termed acquired resistance. This can 
be caused by various adaptive processes such as increased rates of drug efflux, altera-
tions in drug metabolism, selection of subpopulations that carry mutations within the ther-
apeutic target, increased expression of the target molecule, induction of alternative com-
pensatory signalling pathways or inactivation of downstream death signalling pathways 
(Debatin and Krammer, 2004; Lowe et al., 2004; Longley and Johnston, 2005).  
A central feature underlying the resistance mechanisms against targeting agents 
is the persistent activation of either the drug target or its critical downstream signalling 
pathways (Garraway and Jänne, 2012). Secondary mutations lead to decreased compe-
tence of inhibitors by altering contact points for drug binding or by perturbing the confor-
mational state of the kinase. Hence, subpopulations carrying such resistance alleles are 
frequently selected upon treatment (Garraway and Jänne, 2012; Holohan et al., 2013; 
Ramos and Bentires-Alj, 2015). In addition to mutations in the drug target, resistance 
can arise through reactivation of the targeted oncogenic pathway either upstream or 
downstream of the target molecule (Ramos and Bentires-Alj, 2015). For example, tar-
geting of β1 integrin in HNSCC has been shown to induce EGFR signalling which by-
passes the effects of integrin inhibition (Eke et al., 2015). Hence, such kind of resistance 
mechanism has been termed oncogenic bypass or kinome reprogramming, because the 
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primary drug target remains unaltered and continues to be inhibited, but an alternative 
kinase becomes activated (Holohan et al., 2013). This often involves the activation of 
typical cancer associated pathways like the PI3K/Akt/mTOR or MAPK signalling down-
stream of several growth factor receptors to regulate gene expression in response to 
multiple stimuli ultimately controlling cell survival and apoptosis (McCubrey et al., 2011; 
De Luca et al., 2012).  
Considering the use of targeted anticancer therapeutics, it is necessary to under-
stand and integrate the multiple mechanisms of tumour cell adaptation to a given therapy 
to design a combination of targeting agents with conventional therapies to achieve opti-
mal antitumour effects.  
 
2.3.1 Tumour heterogeneity and cancer stem cells 
Besides resistance inducing mutation of drug targets and drug-effect circumventing by-
pass signalling, recent tumour genome profiling studies highlighted an elevated degree 
of intra-tumour heterogeneity and the importance of intrinsically highly resistant cancer 
stem cells (CSCs) (Navin et al., 2010; Valent et al., 2012; Lawrence et al., 2013; Jamal-
Hanjani et al., 2015; Fidoamore et al., 2016). Tumour heterogeneity and CSCs are im-
portant determinants of resistance to chemotherapeutic and targeted agents as well as 
radiotherapy (Bao et al., 2006; Yaromina et al., 2007; Hambardzumyan et al., 2008; 
Chen et al., 2012; Piao et al., 2012). It is increasingly appreciated that tumours are not 
comprised of a uniform cell mass but possess a high degree of molecular and genetic 
diversity. Thus, the therapeutic response to any given anticancer agent is highly likely 
not uniform within the full tumour mass. Consequently, drug resistance to a single ther-
apy can arise through therapy-induced selection of a resistant minor subpopulation of 
cells present in the treatment-naïve tumour (Holohan et al., 2013; Ramos and Bentires-
Alj, 2015). One explanation for the heterogeneity of tumours can be found in the cancer 
stem cell concept, which postulates that diverse cell populations with unique biological 
characteristics exist within the tumour. CSCs are of high importance for anticancer ther-
apy as they possess the capacity to self-renew and to generate the heterogeneous line-
ages of cancer cells that comprise the tumour (Baumann et al., 2008; Valent et al., 2012). 
Accordingly, a particular anticancer therapy can cure a tumour only if all tumour bulk and 
CSCs are eradicated (Dingli and Michor, 2006). Accumulating evidence suggests the 
CSC content to differ between tumours even of the same histopathological type and that 
a higher proportion of CSCs correlates with higher radiochemoresistance (Bao et al., 
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2006; Yaromina et al., 2007; Hambardzumyan et al., 2008; Chen et al., 2012; Piao et al., 
2012).  
Within a tumour, CSCs can reside in specific niches conveying treatment-protec-
tive signals and enabling a subset of cells to survive and re-establish a malignant tumour. 
These niches are defined by various soluble factors such as growth factors, and extra-
cellular matrix components like collagens that critically regulate CSC differentiation, self-
renewal and therapy resistance (Motegi et al., 2014; Gao et al., 2016; Krause et al., 
2017). For brain tumours the perivascular niche (PVN) has been shown to provide an 
ideal microenvironment for cancer cells to resist therapeutic insults. The PVN is com-
posed of various cell types such as astrocytes, microglia, endothelial cells and pericytes 
as well as ECM molecules like collagen type I (Klemm and Joyce, 2014; Motegi et al., 
2014). In preclinical models of medulloblastoma, CSCs located within the PVN have 
been shown to survive irradiation due to enhanced PI3K/Akt signalling (Hambardzumyan 
et al., 2008) or via YAP driven IGF2/Akt activation (Fernandez-L et al., 2012). Activation 
of these pathways allows CSCs to cope with persistent DNA strand breaks, thus contrib-
uting to radioresistance. While the PVN has been studied most extensively in GBM, its 
potential involvement in treatment resistance has also been reported for other tumour 
entities including breast and head and neck cancer as well as melanoma (Klemm and 
Joyce, 2014). Consequently, targeting of cancer stem cell-niche interactions could be an 
attractive approach for cancer therapy. 
In terms of treatment individualisation, specific biological characteristics of CSCs 
may serve as basis to identify resistant subpopulations and have been evaluated for 
many cancer types in preclinical and clinical studies. For example, the putative CSC 
marker CD133 has been intensively investigated in a number of human cancers including 
glioblastoma. CD133 is a membrane glycoprotein and CD133 positive GBM CSCs have 
been suggested to be more resistant to drug treatment and radiotherapy compared to 
CD133 negative cells (Zeppernick et al., 2008; Zhang et al., 2008). However, clinical 
data on the prognostic value of CD133 expression in GBM remain controversial (Lisyaniy 
et al., 2017) and further research to discover biomarkers with translational relevance for 
GBM and other cancers is needed. 
 
2.3.2 Tumour microenvironment and cell-adhesion mediated resistance 
With regard to treatment resistance of tumours and tumour cells, research focusses 
mainly on cell intrinsic parameters such as drug efflux, drug inactivation, altered DNA 
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repair machinery, dysregulation or alteration of the drug targets, upregulation of growth 
factor and survival signalling and evasion of apoptosis (Garraway and Jänne, 2012; 
Holohan et al., 2013; Lawrence et al., 2013). Recently, the complexity of tumours is in-
creasingly appreciated, as they are comprised not only of malignant cells, but also en-
dothelial cells, fibroblasts and immune cells as well as extracellular matrix (ECM), me-
tabolites, oxygen and reactive oxygen species. Furthermore, the essential role of tumour 
cell-microenvironment interactions for cancer initiation, malignant progression, metasta-
sis and resistance development is widely accepted (Barcellos-Hoff and Cordes, 2009; 
Klemm and Joyce, 2014).  
Cell-ECM interactions have been shown to be of central importance for therapy 
resistance (Cordes and Meineke, 2003; Sandfort et al., 2007). The ECM, which is mainly 
produced by fibroblasts, is composed of proteoglycans and fibrillar proteins like colla-
gens, fibronectin, elastin and laminin (Bosman and Stamenkovic, 2003; Guo and 
Giancotti, 2004; Spencer et al., 2007). Additionally, the ECM is enriched with cytokines, 
growth factors and proteolytic proteins such as matrix metalloproteinases (MMPs), that 
play important roles in the constant reorganisation of this highly dynamic compartment 
Figure 2.4. Integrins contribute to cancer drug- and chemoresistance by mediating cell adhesion to 
the extracellular matrix. Upon cell adhesion to extracellular matrix (ECM) proteins integrins induce
prosurvival signalling cascades and therby contribute to cell adhesion-mediated drug and chemoresistance.
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(Spencer et al., 2007). The ECM is an essential component for maintenance of both 
primary and metastatic cancer niches. However, interactions between cancer cells and 
the various components of the ECM go far beyond simple structural support. Cell adhe-
sion to the ECM or isolated matrix components are mainly but not exclusively facilitated 
by the integrin family of cell adhesion molecules (Tabatabai et al., 2011; Seguin et al., 
2015). Moreover, it is generally accepted that cell adhesion molecules fundamentally 
impact on cancer cell therapy resistance as they convey survival- and invasion-promot-
ing microenvironmental cues in numerous cancers including GBM (Cordes and Meineke, 
2003; Cabodi et al., 2010; Desgrosellier and Cheresh, 2010; Eke et al., 2010; Nam et 
al., 2010; Eke et al., 2012; Eke and Cordes, 2014; Dickreuter et al., 2016; Vehlow et al., 
2017). For this phenomenon the terms cell-adhesion mediated drug resistance (CAM-
DR) and cell-adhesion mediated radioresistance (CAM-RR) have been coined (Figure 
2.4 and Cordes and Meineke, 2005; Sandfort et al., 2007). Upon cytotoxic injury, tumour 
cells have been shown to upregulate various integrin subunits on the cell surface provid-
ing improved adhesion of cells to ECM proteins such as fibronectin or laminin. Upon 
irradiation, enforced integrin-clustering was found to trigger FAK, ILK, Akt, GSK3α, 
STAT3 and NFkB signalling indicating modulation of these cascades for determination 
of cellular radiosensitivity (Cordes and Meineke, 2003; Desgrosellier and Cheresh, 2010; 
Klemm and Joyce, 2014). Moreover, β1 integrin has been implicated in the induction of 
bypass signalling cascades upon treatment with the EGFR-inhibitory antibody cetuximab 
in head and neck cancer cells (Eke et al., 2013; Eke et al., 2015). In addition to the 
induction of resistance-mediating bypass signalling axes, cell-ECM interactions have 
been implicated in the modulation of DNA repair pathways (Dickreuter et al., 2016). Es-
pecially in the context of radiotherapy this issue is of great importance as radioresistance 
mainly results from activation of DNA repair mechanisms. Inhibition of β1 integrin was 
found to perturb repair of radiogenic DNA double stand breaks by reducing the activity 
of the error-prone Nonhomologous end joining repair pathways, thereby conveying radi-
osensitisation of head and neck cancer cells (Dickreuter et al., 2016). Taken together, 
these studies indicate the importance of cell-microenvironmental interactions as further 
essential mechanism of therapy resistance and point at the need for the development of 
novel strategies for anticancer treatment. 
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2.3.3 Autophagy 
By altering their anabolic and catabolic pathways, cells respond to changes in their extra- 
and intracellular environment. Two major pathways are involved in the catabolism of cel-
lular material: the multi-enzyme proteasome system and autophagy (Yu et al., 2006; 
Levine and Kroemer, 2008; Fulda and Kögel, 2015). Autophagy includes several degra-
dative mechanisms that involve the delivery of cytoplasmic cargo to the lysosome and 
can be divided into the three subclasses microautophagy, macroautophagy and chaper-
one-mediated autophagy (Codogno and Meijer, 2005; Levine and Kroemer, 2008). The 
most extensively investigated subclass is macroautophagy (herein referred to as autoph-
agy), which is activated in response to different forms of metabolic stress including nu-
trient deprivation, growth factor depletion and hypoxia. Autophagy represents the major 
catabolic mechanism in eukaryotic cells for the degradation of long-lived proteins and 
organelles (Levine and Kroemer, 2008). Autophagy-driven degradation generates free 
amino and fatty acids that can be used by cells for de novo synthesis of proteins as well 
as generation of intracellular nutrients and energy, thereby maintaining cellular biosyn-
thesis and viability during metabolic stresses (Holohan et al., 2013). 
The autophagic process involves the three major steps vesicle nucleation, vesicle 
elongation and vesicle fusion (Levine and Kroemer, 2008; Fulda and Kögel, 2015). Dur-
ing the steps of vesicle nucleation and elongation a so-called isolation membrane is 
formed and expanded to a phagophore. Subsequently, the edges of the phagophore fuse 
around cytoplasmic material and form a double-membraned vesicle, the autophago-
some. Finally, the autophagosome fuses with a lysosome to form an autolysosome for 
degrading the captured material and the inner vesicle membrane (Levine and Kroemer, 
2008). The gold standard to detect the induction of autophagy biochemically or micro-
scopically is the monitoring of autophagosome formation by detection of LC3-II. The pro-
tein LC3 exists in the two forms, LC3-I and its lipidated derivative LC3-II, which are lo-
calised in cytosol (LC3-I) or in autophagosomal membranes (LC3-II). Consequently, 
LC3-II serves as ideal marker for autophagosome formation (Kabeya et al., 2000; 
Klionsky et al., 2008). 
Autophagy is a tightly controlled degradation process and several proteins have 
been implicated in autophagy regulation. In mammals, one of the key regulators of au-
tophagy is mTOR, which is the major inhibitory signal to repress autophagy in the pres-
ence of growth factors and abundant nutrients (Lum et al., 2005). Downstream of mTOR, 
ATG proteins control the progression of the autophagic process. The initial step of vesicle 
nucleation, for example, is controlled by ATG14, Vps34 and Vps15 forming the 
    Background 
17 
 
autophagy-core complex together with Beclin-1 (ATG6) (Funderburk et al., 2010). Be-
sides mTOR, other important autophagy regulators such as AMPK, eIF2α, Bcl-2/Bcl-XL, 
p53, DAPk, JNK and Erk1/2 have been identified in various normal and cancer cell mod-
els (Gozuacik and Kimchi, 2004; Codogno and Meijer, 2005; Fulda and Kögel, 2015).  
In addition to its physiological role as quality-control and homeostasis mechanism, 
several genetic links between deficient autophagy and cancer have emerged providing 
increasing support for the concept of autophagy as a tumour suppressor pathway (Levine 
and Kroemer, 2008; Fulda and Kögel, 2015; Galluzzi et al., 2016). Numerous studies 
report a strong correlation between molecules involved in autophagy induction and tu-
mour suppression as well as molecules involved in autophagy inhibition and oncogene-
sis (Levine and Kroemer, 2008). Moreover, cancer cells were shown to frequently hijack 
the prosurvival function of autophagy to resist therapeutic challenge (Gozuacik and 
Kimchi, 2004; Codogno and Meijer, 2005) and many anticancer therapies including 
chemo-, radio- and targeted therapies have been shown to activate autophagic path-
ways. This indicates that autophagy activation represents a cellular attempt to cope with 
stress induced by cytotoxic agents (Holohan et al., 2013). Hence, inhibition of autophagy 
might be beneficial in cancer treatment and has stimulated preclinical and clinical re-
search with the aim to modulate the autophagic process for therapy sensitisation. Multi-
ple clinical trials are currently testing the autophagy inhibitors chloroquine or hy-
droxychloroquine (thus far, the only FDA approved drugs) in combination with various 
conventional treatment modalities in efforts to enhance the response to treatment 
(Gewirtz, 2014). 
 
2.4 Discoidin Domain Receptor 1 (DDR1) 
2.4.1 Structure 
The two discoidin domain receptors DDR1and DDR2 were first discovered by several 
groups in the 1990s based on homology cloning with the intention to discover novel RTK 
gene products. These groups reported the isolation of a novel class of transcripts encod-
ing proteins with an N-terminal discoidin I-like domain and a C-terminal kinase domain 
(Johnson et al., 1993; Karn et al., 1993; Di Marco et al., 1993; Zerlin et al., 1993; Lai and 
Lemke, 1994; Laval et al., 1994; Perez et al., 1994; Sánchez et al., 1994; Alves et al., 
1995; Perez et al., 1996).  
    Background 
18 
 
 Further genetic analysis revealed that the DDR1 gene maps to human chromo-
some 6 (6p21.3), spans 24 kb and comprises 17 exons. The extracellular domain is en-
coded by exons 1–8 and the transmembrane domain by exon 9. Exons 10–12 encode 
the cytosolic juxtamembrane (JM) domain, with the remaining exons predominantly cod-
ing for the kinase domain (Playford et al., 1996). On the structural level, DDR1 is a type 
I transmembrane protein that displays a general organisation typical for many members 
of the RTK family. The presence of two extracellular domains is a unique structural char-
acteristic of both discoidin domain receptors. N-terminally DDR1 possess a discoidin 
domain, tightly linked to a discoidin-like domain which facilitate collagen binding (Carafoli 
and Hohenester, 2013). These globular domains are followed by a highly flexible extra-
cellular JM region of about 50 amino acids and a transmembrane domain (Xu et al., 
2014). After the transmembrane domain, the DDRs contain unusually large cytosolic JM 
regions, which are up to 171 amino acids in size depending on the protein isoform. C-
terminally DDR1 is composed of a catalytic kinase domain of about 300 amino acids 
followed by very short C-terminal tail (Alves et al., 1995).  
Five different DDR1 isoforms (DDR1a-e) have been identified that are generated 
by alternative splicing (Figure 2.5). While the two most abundant DDR1 isoforms, DDR1a 
and DDR1b, are generated by alternative splicing of exons 10–12 (DDR1a is lacking 
exon 11), DDR1c contains 6 additional amino acids in the kinase domain (Alves et al., 
1995; Leitinger, 2014). DDR1a-c contain a catalytically active kinase domain and are 
therefore fully functional receptor tyrosine kinases. Two kinase deficient variants, DDR1d 
and DDR1e, are generated by further alternative splicing. DDR1d lacks exons 11 and 
Figure 2.5. Genomic structure of DDR1 isoforms. (a) Schematic of the genomic structure of the five 
different DDR1 isoforms a-e. Boxes represent single exons. Crossed boxes of DDR1e represent a frameshift 
leading to kinase deficiency.(b) Schematic of the DDR1 Structure. Discoidin (DS) and discoidin-like (DS-
like) domain facilitate extracellular collagen binding. 
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12, while DDR1e additionally misses the first half of exon 10 (Figure 2.5 and Alves et al., 
2001). These alternative splicing events lead to formation of truncated proteins deficient 
for either the entire kinase domain or parts of the JM domain and the ATP-binding site. 
To date, the biological function of these two kinase-deficient DDR1 isoforms is not fully 
understood, but it is speculated that DDR1d and DDR1e could modify DDR1-dependent 
signalling if co-expressed with full-length receptors (Leitinger, 2014).  
 
2.4.2 Physiological role of DDR1 
The ECM critically controls cancer cell behaviour by inducing signalling pathways that 
regulate cell proliferation, survival, migration, and invasion (Lu et al., 2011). As major 
part of the ECM, collagens alter tissue density and architecture in cancer to promote 
tumour formation and metastasis (Provenzano et al., 2006; Provenzano et al., 2008). 
Moreover, collagen type I was shown to populate microenvironmental niches where GBM 
stem cells reside, survive treatment and propagate into recurrence (Motegi et al., 2014; 
Gao et al., 2016). Until recently, tumour-ECM interactions mediating prosurvival and re-
sistance promoting signals were exclusively attributed to integrins. The identification of 
the Discoidin Domain Receptors (DDRs) added new representatives to the group of col-
lagen receptors (Rammal et al., 2016). In cell culture models, DDR1 and DDR2 were 
shown to interact with several collagen types in their native triple-helical conformation 
(Shrivastava et al., 1997; Vogel et al., 1997). While fibrillar collagens (types I, II, III, V, 
and XI) are ligands for both DDRs (Shrivastava et al., 1997; Vogel et al., 1997), nonfi-
brillar collagens are recognised with distinct preferences. The basement membrane col-
lagen type IV as well as collagen type VIII are exclusively recognised by DDR1, while 
DDR2 shows specificity for collagen type X (Valiathan et al., 2012). Upon collagen bind-
ing, the DDRs undergo autophosphorylation with very slow and sustained kinetics 
(Shrivastava et al., 1997; Vogel et al., 1997) that is distinct from other RTKs typically 
showing fast and transient activation kinetics. Active DDRs regulate key cellular pro-
cesses like cell differentiation, cell proliferation, cell survival and cell migration as well as 
ECM remodelling through interaction with MMPs and are therefore discussed as poten-
tial cancer drivers (Leitinger, 2014). While DDR1 expression is predominant in epithelial 
cells, DDR2 is found in cells of connective tissues that originate from embryonic meso-
derm (Alves et al., 1995). High levels of DDR1 mRNA are found in human brain, lung, 
kidney, spleen, and placenta (Johnson et al., 1993; Di Marco et al., 1993; Laval et al., 
1994; Perez et al., 1994; Perez et al., 1996). DDR2 mRNA is highly expressed in skeletal 
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and heart muscle, kidney and lung (Karn et al., 1993; Lai and Lemke, 1994). Both DDRs 
possess a motif in their extracellular domain with homology to the protein discoidin-I 
(Johnson et al., 1993; Di Marco et al., 1993), which was originally isolated from the slime 
worm Dictyostelium discoideum and shown to mediate cell aggregation (Breuer and Siu, 
1981; Springer et al., 1984). Physiologically, experiments in DDR1-knockout mice re-
vealed an important role of DDR1 in the pre-implantation adhesion between the luminal 
epithelium and the blastocyst. Due to defects in blastocyst implantation, female animals 
were mostly infertile. Compared to mice that express DDR1, DDR1-knockout mice that 
survive gestation are smaller, show defects in the development of mammary glands, 
poorly calcified fibula bone and a narrower pelvis (Vogel et al., 2001). Both DDRs can 
control cell migration and adhesion, but apart from roles in wound healing (DDR2) and 
immune responses (DDR1), it is not clear how these functions relate to physiological 
processes where DDR-mediated cell migration or adhesion is required in healthy adults 
(Leitinger, 2014). 
 
2.4.3 DDR1 in cancer 
Among the different cancer entities DDR1 has been studied in, the most advanced stud-
ies have been undertaken in lung cancer. For non-small cell lung cancer (NSCLC) pa-
tients, numerous observations report DDR1 mutations as well as dysregulated expres-
sion and phosphorylation. In a set of 150 biopsies from NSCLC patients DDR1 and 
DDR2 were among the 20 most highly phosphorylated RTKs (Rikova et al., 2007). Fol-
lowing Met and ALK, this phosphoproteomic study found DDR1 to be the third most 
phosphorylated tyrosine kinase in NSCLC patients suggesting an association of en-
hanced DDR1 activation and NSCLC development and progression. Similarly, DDR1 
mRNA levels were found to be upregulated in a tumour vs. normal tissue analysis on 
146 primary NSCLC and in an independent set of 23 matched tumour and normal lung 
tissue samples (Ford et al., 2007). Studying an aggressive phenotype of KRAS-driven 
lung adenocarcinomas, Ambrogio et al. found DDR1 to be the top scoring gene associ-
ated with tumour aggressiveness. Subsequent genetic and pharmacological inhibition of 
DDR1 blocked tumour initiation and progression (Ambrogio et al., 2016) arguing for 
DDR1 targeting as an potential treatment approach for patients with KRAS/TP53-driven 
lung adenocarcinoma. Besides overexpression in lung cancer, DDR1 was also identified 
as one of 72 significantly upregulated genes in malignant versus benign pancreatic en-
docrine tumours (Couvelard et al., 2006).  
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Importantly, DDR1 has also been implicated in gliomagenesis. High DDR1 mRNA 
expression was found to correlate with high tumour grade in pediatric (Weiner et al., 
1996) and adult brain tumours (Weiner et al., 2000). In line, Ram et al. found elevated 
DDR1 expression in GBM compared to normal brain tissue as well as DDR1a and 
DDR1b to be involved in GBM invasiveness (Ram et al., 2006). In a study on tumour 
tissue of 29 patients with malignant gliomas, high DDR1 expression was found to 
strongly and consistently correlate with short-term patient survival, GBM proliferation and 
invasion (Yamanaka et al., 2006). Furthermore, a role of DDR1 for the homeostasis of 
brain tumour initiating cells was suggested in a study applying single-cell molecular pro-
filing on GBM stem-like cells (GSCs) (Rennert et al., 2016). Besides these initial studies 
suggesting a potential role of DDR1 for GBM progression, stemness, invasiveness and 
patient outcome, the molecular mechanisms triggered by DDR1 and essentially contrib-
uting to gliomagenesis are yet unknow.  
The contribution of DDR1 in tumour development and progression clearly indicates 
that DDR1 targeting might represent a promising therapeutic strategy and great efforts 
have been undertaken to find specific DDR1 targeting agents (Rammal et al., 2016). 
Using chemical and proteomic approaches, dasatinib, imatinib, nilotinib (Bantscheff et 
al., 2007; Rix et al., 2007; Day et al., 2008) and ponatinib (Canning et al., 2014) were 
identified as potent small-molecule inhibitors against DDR1 and DDR2. Originally, these 
substances were developed to inhibit Bcr-Abl tyrosine kinase in chronic myeloid leuke-
mia. While the aforementioned substances are representatives of rather broad kinase 
inhibitors, two promising compounds, 7rh and 7rj, have been developed to specifically 
inhibit the kinase activity of DDR1. Both targeting agents revealed potent growth sup-
pression of cancer cell lines expressing high levels of DDR1 including A549 and NCI-
H23 lung carcinoma, MDA-MB-435, MCF-7, and T47D breast carcinoma and HCT116 
colon carcinoma cells (Gao et al., 2013). Kim et al. designed and synthesised a series 
of type II kinase inhibitors among which DDR1-IN-1 induced a significant inhibitory effect 
of DDR1. This inhibitor was able to specifically inhibit DDR1 activation in U2OS cells in 
the presence of collagen (Kim et al., 2013). So far, none of these more specific DDR1 
inhibiting agents has been tested in clinical trials, but their development paved the way 
to more translational approaches testing DDR1 targeting as potential therapeutic strat-
egy. 
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2.4.4 DDR1 signalling 
RTKs are activated by ligand binding leading to subsequent autophosphorylation of cy-
toplasmic tyrosine residues and induction of intracellular signalling cascades. Thereby, 
RTKs transduce extracellular signals to the cytoplasm. A typical requirement for sufficient 
autophosphorylation is receptor dimerization upon ligand binding. Dimerization is neces-
sary to bring the kinase domains into close proximity and allow trans-phosphorylation of 
tyrosine residues in the JM and kinase domains (Lemmon and Schlessinger, 2010).  
In contrast to classical growth factor-binding RTKs, DDR1 forms ligand-independ-
ent stable dimers that are non-covalently linked and potentially formed during biosynthe-
sis (Noordeen et al., 2006; Mihai et al., 2009). DDR1 dimer clustering and oligomerisation 
upon collagen binding enables trans-phosphorylation of neighbouring collagen-unbound 
DDR1 dimers facilitating signal amplification (Juskaite et al., 2017). Moreover, DDR1 
dimerization involves multiple contacts in the extracellular and transmembrane domain 
as well as in intracellular regions, with the transmembrane domain being a key region for 
dimerization (Noordeen et al., 2006; Juskaite et al., 2017). Remarkably, upon collagen 
binding, DDR1 exhibits delayed and sustained receptor phosphorylation that is distinct 
from other RTKs. Typically, RTKs are activated within seconds to minutes after ligand-
binding. Full DDR1 activation, on the opposite, is often achieved hours after stimulation 
with collagen and can remain up to several days post-stimulation (Shrivastava et al., 
1997; Vogel et al., 1997). Currently, the understanding about how collagen binding is 
translated to kinase activation and how long-lived phosphorylation of DDR1 molecularly 
contributes to intracellular signalling is lacking.  
Similarly, only little is known about the molecular mechanism of DDR1 transmem-
brane signalling in normal epithelial and cancer cells. In smooth muscle and mammary 
epithelial as well as in transfected embryonic kidney cells DDR1 was found to activate 
the MAPK pathway via activation of Erk1/2 (Figure 2.6 and Hilton et al., 2008; Lu et al., 
2011; Abbonante et al., 2013). Additionally, in a variety of human normal and cancer cell 
lines as well as mouse embryonic stem cells, DDR1 was shown to induce PI3K/Akt sig-
nalling (Figure 2.6 and Ongusaha et al., 2003; Hahn et al., 2010). In breast and colon 
carcinoma cell lines DDR1 activation has been linked to prosurvival signals upon geno-
toxic stress (Ongusaha et al., 2003) and has led to increased chemoresistance of breast 
cancer cells via activation of the NFκB axis (Figure 2.6 and Das et al., 2006). Moreover, 
Notch1 signalling was found to mediate DDR1-dependent prosurvival effects in colon 
carcinoma cells (Kim et al., 2011).  
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Likewise, DDR1 was found to cooperate with other collagen binding receptors of 
the integrin family. DDR1 signalling via a β1 integrin/p130CAS/JNK axis was detected in 
pancreatic cancer cells resulting in upregulation of N-cadherin and EMT-like cell scatter-
ing (Figure 2.6 and Shintani et al., 2008). Similarly, cooperation between DDR1 and α2β1 
promotes the self-renewal of mouse embryonic stem cells through cell cycle regulation 
(Hahn et al., 2010). Overexpression of DDR1 resulted in enhanced α2β1 and α5β1 acti-
vation in focal adhesions and increased membranous expression in mouse embryonic 
fibroblasts (Xu et al., 2012; Staudinger et al., 2013). These studies suggest an involve-
ment of DDR1 in control of receptor trafficking and recycling, which is commonly 
achieved by endocytosis. To date, only one study showed direct evidence of rapid DDR1 
internalisation via endocytosis and endosomal DDR1 signalling upon stimulation by col-
lagen (Mihai et al., 2009). In line, DDR1b and DDR1c possess a tyrosine-based NPXY 
motif in their intracellular JM region that directs membrane proteins to clathrin-coated 
pits, which represent the initial structures for clathrin-mediated endocytosis (Bonifacino 
Figure 2.6. DDR1 signalling in cancer. Schematic of uncovered DDR1 signalling pathways in cancer 
showing that DDR1 contributes to cancer development and progression via stimulation of EMT-like cell-
scattering, pro-survival and anti-apoptotic signalling. 
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and Traub, 2003). But how and to which extend DDR1 endocytosis and endosomal sig-
nalling contribute to DDR1-driven stimulation of intracellular pathways remains elusive. 
 
.
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3 Hypothesis and Aims 
Glioblastoma is the most common and the pathologically most aggressive form of astrocytic 
brain tumours in adults. Even though the efficacy of multimodal therapies comprising neuro-
surgery, chemo- and radiotherapy continuously improved over the last decades, GBM is still 
associated with a poor prognosis and a survival range of 9-15 months. Short-term survival is 
due to genetic and epigenetic alterations in resistance inducing genes and severe destructive 
infiltration of normal tissue. As a further source of therapy resistance, integrins are generally 
accepted as potential therapeutic targets for the treatment of several cancers including GBM. 
However, the integrin inhibitor cilengitide failed to improve patient outcome in a phase III clini-
cal trial on glioblastoma patients. Similar to integrins, DDR1 binds to collagens facilitating a 
linkage of the ECM to the intracellular cytoskeleton as well as cell adhesion and cell-matrix 
communication. In GBM, elevated DDR1 mRNA expression potentially correlates with poor 
prognosis, advanced tumour stage, invasiveness and stemness, but despite first evidence for 
a putative involvement of DDR1 in GBM pathogenesis, the underlying mechanisms are un-
solved.  
Consequently, we hypothesise in the present study that DDR1 fundamentally impacts on 
GBM cell survival upon radiochemotherapy as well as GBM invasion and that targeting DDR1 
elicits therapy sensitisation and prolonged survival. Hence, the aims of the presented project 
are to identify the role of DDR1 on cellular radiochemosensitivity and invasiveness in vitro and 
in vivo and untangle the underlying signalling mechanisms. In line, genetic and pharmacolog-
ical inhibition of DDR1 are used to evaluate the effects of the receptor tyrosine kinase on tu-
mour cell survival and invasiveness using GBM cell lines, primary GBM stem-like cells and an 
orthotopic GBM mouse model. The mechanisms contributing to DDR1 induced radiochemo-
resistance are assessed by broad spectrum phosphoproteome analysis and direct interaction 
partners linking DDR1 to the affected pathways are identified using mass spectrometry, co-
immunoprecipitations and FRET analysis. Furthermore, the cell death mechanisms underlying 
the effects of DDR1 inhibition are identified. 
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4 Materials and Methods 
4.1 Materials 
4.1.1 Devices 
Table 4.1. Devices used for biochemical, molecular-biological, cell culture or in vivo applications. 
Device Type Company 
Autoclave V-65 Systec, Wettenberg, D 
Barometer  Conrad Electronics, Hirschau, D 
Binocular, incl. light source Stemi2000 Carl Zeiss, Jena, D 
Bio Imaging System  Genius Syngene Syngene, Cambridge, GB 
Centrifuge 5415R (for 15, 50 ml reac-tion tubes) Eppendorf, Hamburg, D 
Centrifuge S415R (for 1,5 ml Safe-Lock reaction tubes) Eppendorf, Hamburg, D 
Dosimeter PTW Unidos PTW, Freiburg, D 
Film welding tool Dual Electronic Jencons-PLS, London, GB 
Freezer, -20 °C KX1011 Liebherr, Ochsenhausen, D 
Freezer, -80/ -150 °C  Heraeus Holding GmbH, Ha-
nau, D 
Fridge  Liebherr, Ochsenhausen, D 
Gel electrophoresis-System 
for LDH-Analysis 
Paragon® Electrophoresis 
System 
Beckmann Instruments, Fuller-
ton, USA 
Hand drill Xenox Nail 35k Xenox, Föhren, D 
Ice machine AT-10 Scotsman, London, GB 
Incubator bacteria  Memmert, Schwabach, D 
Incubator cell culture HeraCel Heraeus Holding GmbH, Ha-
nau, D 
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Device Type Company 
Incubator for liquids  Heraeus Holding GmbH, Ha-
nau, D 
Inverted Microscope Axiovert 25 Carl Zeiss, Jena, D 
Laser Scanning Microscope 
(LSM) 
Axiovert 200M,  
LSM 510 Meta 
Carl Zeiss, Jena, D 
Microwave  Sharp Electronics (Europe) GmbH, Hamburg, D 
PCR cycler Mastercycler epgradient Eppendorf, Hamburg, D 
pH-meter ph Level 1 inoLab, Weilheim, D 
Power Supply EPS601 Amersham, Freiburg, D 
Precision scale LE244S-0CE Sartorius, Göttingen, D 
Rotary shaker CERTOMAT®IS B. Braun Melsungen AG, Melsungen, D 
Scale BL 1500S Sartorius, Göttingen, D 
Semi Dry Blotter TE77 Amersham, Freiburg, D 
Shaker Polymax 1040, 2040 Heidolph, Schwabach, D 
Shaker KS260 basic IKA, Staufen, D 
Spectrophotometer Nano-Drop-1000 PEQLAB Biotechnologie GmbH, Erlangen, D 
Stirrer, incl. heating MR3001 Heidolph, Schwabach, D 
Sterile work bench Clean Air  Heraeus Holding GmbH, Ha-
nau, D 
Stereotactic instrument Just for Mouse Stereotaxic Instrument STO-51730 Stoelting Co., Wood Dale, IL 
Tecan Microplate-Reader Genios Pro Tecan, Crailsheim, D 
Thermomixer comfort 1,5 ml Eppendorf, Hamburg, D 
Vacuum pump Vacusafe comfort VacuSafe IBS Integra Biosci-
ence, Chur, CH 
Vertical gel-electrophoresis 
chamber incl. accessory 
parts 
SE250 Hoefer, San Francisco, USA 
Vortex mixer Reax control VWR, Darmstadt, D 
Water bath SW22 Julabo Labortechnik GmbH, Seelbach, D 
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Device Type Company 
X-ray device Y.TU320 Yxlon, Kopenhagen, DK 
 
4.1.2 Further materials 
Table 4.2. Materials used for biochemical, molecular-biological, cell culture or in vivo applications. 
Material Company 
Cell culture flasks; T-25, T-75, T-175 cm2 Corning Life Science, Wiesbaden, D 
Cell culture plates, 96-Well, flat bottom Corning Life Science, Wiesbaden, D 
Cell culture plates, 96-Well, round bottom Corning Life Science, Wiesbaden, D 
Cell culture plates; 6-, 12-, 24-Well BD, Heidelberg, D 
Cell culture plates; 60 mm, 100 mm BD, Heidelberg, D 
Cell scraper; 40 cm BD, Heidelberg, D 
Centrifuge tubes; 15 ml, 50 ml Greiner Bio-one GmbH, Frickenhausen, D 
Coverslips, 12 mm, round Glaswarenfabrik Karl Hecht KG, Sondheim, D 
Cryo vials Biochrom, Berlin, D 
Film cassette Amersham, Freiburg, D 
Glass pasteurpipets Brand GmbH u. Co. KG, Wertheim, D 
Glutathione-sepharose beads GE Health Care, Freiburg, D 
Hamilton-Syringe, 100 µl Hamilton Bonaduz AG, Bonaduz, CH 
Hamilton-Syringe, 10 µl Hamilton Bonaduz AG, Bonaduz, CH 
HyperTM ECL-films Amersham, Freiburg, D 
Instrument case Roth, Karlsruhe, D 
Insulin syringe, 0,3 mm x 12 mm Braun, Melsungen, D 
Labory bottles Schott AG, Mainz, D 
Nitrocellulose membrane Protran; 0,2 µm Schleicher & Schuell, Dassel, D 
Microscopy slides, Superfrost Roth, Karlsruhe, D 
Pipette tips with filter, sterile; 10-1000 µl Sarstedt, D 
Pipettes; 1, 5, 10, 25 ml BD, Heidelberg, D 
Pipette controller, accu jet pro Brand, Herrenberg, D 
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Material Company 
Protein A/G beads, 50% slurry Alpha Diagnostics, Paramus, USA 
Reaction tube, Safe Lock; 1,5 ml, 2 ml Eppendorf, Hamburg, D 
Reaction tube rack Rotilab, Roth, Karlsruhe, D 
Staining chamber Roth, Karlsruhe, D 
Whatman filterpaper; 3 mm Bender-Hobein, Zürich, CH 
 
4.1.3 Patient material 
Brain tumour specimens were obtained from clinically documented material of patients 
who underwent neurosurgery for resection of primary glioblastoma WHO grade IV. Pa-
tients gave written consent as it was intended by the local ethics committee of Philipps-
University of Marburg (Reference Number 185/11 – 13 patients for immunohistochemical 
investigations) and Technische Universität Dresden, Germany (approval no. 
AZ152052013 – establishment of primary cell cultures). 
4.1.4 siRNA 
Table 4.3. Small interfering (si) RNAs used to silence the indicated genes. Corresponding sequences are 
shown. 
siRNA Sequence (Sense) Company 
Akt1#1 5‘-GGCCCAACACCUUUAUCAUtt-3‘ MWG Eurofins, Ebersberg, D 
Akt1#2 5‘-GGUAUUUCGAUGAGGAGUUtt-3‘ MWG Eurofins, Ebersberg, D 
Akt1#3 5‘-GCACCGUGUGACCAUGAACtt-3‘ MWG Eurofins, Ebersberg, D 
Beclin-1#1 5’-GCUCAGUAUCAGAGAGAAUtt-3’ MWG Eurofins, Ebersberg, D 
Beclin-1#2 5’-ACUCAACACUGGCUAAUUAtt-3’ MWG Eurofins, Ebersberg, D 
DDR1#2  5‘-GAGCGUCUGUCUGCGGGUAtt-3‘ MWG Eurofins, Ebersberg, D 
DDR1#3 5‘-GCCAGUGACACUAAAACAAtt-3‘´ MWG Eurofins, Ebersberg, D 
Raptor#1 5‘-GCGGAGAGCUCAUCAACAAtt-3‘ MWG Eurofins, Ebersberg, D 
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Raptor#2 5‘-GGACAACGGCCACAAGUACtt-3‘ MWG Eurofins, Ebersberg, D 
Rictor#1 5’-GCAGUAAAUUAUAUGCCAAtt-3‘ MWG Eurofins, Ebersberg, D 
Rictor#2 5‘-GCAGCCUUGAACUGUUUAAtt-3 MWG Eurofins, Ebersberg, D 
Nonspecific siRNA 5’-GCAGCUAUAUGAAUGUUGUtt-3’ MWG Eurofins, Ebersberg, D 
 
4.1.5 Inhibitors 
Table 4.4. Inhibitors used for cell culture and in vivo experiments.  
Inhibitor Target Company 
DDR1-IN-1 DDR1 Tocris 
 
4.1.6 Chemotherapeutic agents 
Table 4.5. Chemotherapeutics used for cell culture and in vivo experiments.  
Chemotherapeutic agent Company 
Temozolomide (TMZ) MSD Sharp & Dohme 
 
4.1.7 Plasmids 
Applied plasmids are described in Table 4.6. The pRK5-DDR1b plasmid (Xu et al., 2014) 
was used to amplify DDR1 cDNA by PCR as described in 4.2.15.1. DDR1 cDNA was 
cloned into pmCherry-N1 plasmid to generate a red fluorescent DDR1 fusion protein 
(DDR1WT-mCherry), or into pGST-N1 plasmid to generate DDR1-GST fusion proteins 
(DDR1WT-GST, DDR1ΔKD-GST, DDR1ΔICD-GST, DDR1S448A-GST, DDR1S889A-
GST, DDR1AA-GST). A green fluorescent 14-3-3 fusion protein was established by PCR 
amplification using freshly generated placenta cDNA and the pEGFP-N1 vector (14-3-3-
EGFP). Corresponding empty vectors were used as control. 
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Table 4.6. Plasmids used for cloning, overexpression, fluorescence microscopy and pulldown experi-
ments. 
Plasmid Resistance Specification Supplier 
pRK5-DDR1b AmpR Expression vector expressing DDR1 isoform b, CMV-Promotor 
Birgit Leit-
inger, London, 
UK 
pmCherry-N1 KanR, NeoR 
Expression vector for generation 
of fusion proteins; high copy num-
ber; CMV-Promotor 
Clontech 
pDDR1WT-pmCherry KanR, NeoR 
Expression vector expressing 
DDR1 isoform b-mCherry, high 
copy number; CMV-Promotor 
 
pEGFP-N1 KanR, NeoR 
Expression vector for generation 
of fusion proteins; high copy num-
ber; CMV-Promotor 
Clontech 
p14-3-3-EGFP KanR, NeoR 
Expression vector expressing 14-
3-3-EGFP; high copy number; 
CMV-Promotor 
 
pGEX-6P-1 AmpR Bacterial expression vector for generation of fusion proteins 
Anna Du-
brovska, Dres-
den, D 
pGST-N1 KanR, NeoR 
Expression vector for generation 
of fusion proteins; high copy num-
ber; CMV-Promotor 
 
pDDR1WT-GST KanR, NeoR 
Expression vector expressing 
DDR1 isoform b-GST; high copy 
number; CMV-Promotor 
 
pDDR1ΔKD-GST KanR, NeoR 
Expression vector expressing 
DDR1 isoform b-GST with a de-
leted kinase domain; high copy 
number; CMV-Promotor 
 
pDDR1ΔICD-GST KanR, NeoR 
Expression vector expressing 
DDR1 isoform b-GST with a de-
leted intracellular domain; high 
copy number; CMV-Promotor 
 
pDDR1S448A-GST KanR, NeoR 
Expression vector expressing 
DDR1 isoform b-GST point mu-
tated at position 448 to express 
alanine instead of serine; high 
copy number; CMV-Promotor 
 
pDDR1S889A-GST KanR, NeoR 
Expression vector expressing 
DDR1 isoform b-GST point mu-
tated at position 889 to express 
alanine instead of serine; high 
copy number; CMV-Promotor 
 
pDDR1AA-GST KanR, NeoR 
Expression vector expressing 
DDR1 isoform b-GST point mu-
tated at position 448 and 889 to 
express alanine instead of serine; 
high copy number; CMV-Promotor 
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4.1.8 Primers 
Table 4.7. Primers used to amplify and flank the indicated genes with the indicated restriction sites. Re-
spective sequences are shown. 
Primer Sequence (Sense) Company 
14-3-3WT-F-111 5’-GGAAGATCTGAGAGACTGAGCTGATC  AG-3’ 
MWG Eurofins, 
Ebersberg, D 
14-3-3WT-R-112 5’-ACGCGTCGACTTAG-TTTTCAGCCCCTT CTGC-3’ 
MWG Eurofins, 
Ebersberg, D 
DDR1_pmCherry_F_238 5’-CGCGGTACCGCGGGCCACCATGG-GAC CAGAGGCCCTGTC-3’ 
MWG Eurofins, 
Ebersberg, D 
DDR1_pmCherry_R_239 5’-CGGGGATCCCCGCGCACCGTGTT-GAG TGCATCCTC-3’ 
MWG Eurofins, 
Ebersberg, D 
DDR1WT-NheI-F-100 5’-TAGCTAGCGGCCACCATGGGACCAGA GGCCCTGTCA-3’ 
MWG Eurofins, 
Ebersberg, D 
DDR1WT-KpnI-R-101 5’-CGGGGTACCCACCGTGTTGAGTGCAT CCTC-3’ 
MWG Eurofins, 
Ebersberg, D 
DDR1∆KD-KpnI-R-102 5’-CGGGGTACCTCGAGATCGAGGGAAAT CCAC-3’ 
MWG Eurofins, 
Ebersberg, D 
DDR1∆ICD-KpnI-R-103 5’-CGGGGTACCGAGCATGAGGG-CAATGA TGAG-3’ 
MWG Eurofins, 
Ebersberg, D 
GST-AgeI_F_280 5’-CGGACCGGTGCCACCATGTCCCCTAT ACTAGGTTATTG-3’ 
MWG Eurofins, 
Ebersberg, D 
GST-XbaI_R_281 5’-CTAGTCTAGATCAGTCACGATGCGGC CGCTCG-3’ 
MWG Eurofins, 
Ebersberg, D 
pGST-DDR1-1341-F-106 5’-GCGCAGGCTCCTCGCCAAGGCTGAA CGGAG-3‘ 
MWG Eurofins, 
Ebersberg, D 
pGST-DDR1-1341-R-107 5‘-CTCCGTTCAGCCTTGGCGAGGAGCCT GCGC-3‘ 
MWG Eurofins, 
Ebersberg, D 
pGST-DDR1-2664-F-108 5‘-GATGCTTCGGTGCTGGGCCCGG-GAGT CTGAGC AG-3‘ 
MWG Eurofins, 
Ebersberg, D 
pGST-DDR1-2664-R-109 5‘-CTGCTCAGACTCCCGGGCCCAG-CACC GAAGCATC-3‘ 
MWG Eurofins, 
Ebersberg, D 
 
4.1.9 Polymerases, Restriction enzymes and ligases 
For PCR, HotStar Plus Polymerase with the corresponding 10x PCR Buffer was used 
(Quiagen, Hilden, D). High fidelity restriction enzymes and appropriate restriction buffers 
(Kpn I, Bam HI, Nhe I, Bgl II and Sal I) were purchased from NEB (Frankfurt a.M., D. T4 
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DNA ligase and the corresponding reaction buffer were purchased from NEB (Frankfurt 
a.M., D).  
4.1.10 Bacterial culture 
Competent DH5α E.coli were purchased from NEB (Frankfurt a.M., D) and cultured on 
LB agar plates or in LB medium (Table 4.8). Successful and correct PCR amplification 
and ligation into the target-vector was ensured by sequencing and agarose-gel electro-
phoresis. 
 
Table 4.8. Composition of media used to culture bacteria. 
Medium Composition Company 
LB medium 
10 g Tryptone 
5 g Yeast extract 
Ad 1 l H2O  
pH adjusted to 7.0 using 10 M 
NaOH 
AppliChem GmbH, Darmstadt, D 
AppliChem GmbH, Darmstadt, D 
 
AppliChem GmbH, Darmstadt, D 
SOC 
20 g Tryptone 
5 g Yeast extract 
0.5 g NaCl 
2.5 ml 1 M KCl 
20 ml sterile 1 M glucose 
AppliChem GmbH, Darmstadt, D 
AppliChem GmbH, Darmstadt, D 
AppliChem GmbH, Darmstadt, D 
AppliChem GmbH, Darmstadt, D 
AppliChem GmbH, Darmstadt, D 
 
To prepare agar plates 1 l LB medium was mixed with 15 g Agar (AppliChem GmbH, 
Darmstadt, D). Selection medium was prepared using a final concentration of 100 µg/ml 
Ampicillin (AppliChem GmbH, Darmstadt, D) or 30 µg/ml Kanamycin (AppliChem GmbH, 
Darmstadt, D). 
 
4.1.11 Protein and DNA ladders 
The PageRuler Unstained (ThermoFisher Scientific, Erlangen, D) was applied as protein 
ladder for SDS gel electrophoresis, the 1 kb DNA ladder (NEB, Frankfurt a.M., D) was 
used for agarose gel electrophoresis.  
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4.1.12 Method kits 
Table 4.9. Method kits used for biochemical applications. 
Kit Application Company 
BCA Protein Assay Kit Determination of protein concentration Pierce, Bonn, D 
ECL Western Blotting 
Detection Reagents Western blot detection 
Amersham, Frei-
burg, D 
Tyramide Signal Ampli-
fication Kit TSATM Immunohistochemistry 
Life Technologies, 
Karlsruhe, D 
QuikChange II Site-Di-
rected Mutagenesis Kit Site directed mutagenesis 
Agilent, Wald-
bronn, D 
NucleoSpin® Gel and 
PCR cleanup kit 
Cleanup of PCR products or vectors after en-
zymatic digestion 
Macherey & 
Nagel, Düren, D 
 
4.1.13 Primary antibodies 
Table 4.10. Primary antibodies used for Western blot, immunoprecipitation, immunofluorescence or im-
munohistochemical applications.  
Antibody Application Dilution Company 
14-3-3 (pan), rabbit, 
polyclonal 
Western blot 
Immunoprecipitation 
1:1000 
10 µl 
Abcam, Cambridge, UK 
14-3-3 (pan), mouse, 
polyclonal 
Western blot 
Immunofluorescence 
1:1000 
1:50 
Abcam, Cambridge, UK 
β-Actin, Klon AC-15, 
mouse, monoclonal Western blot 1:10000 
Sigma Aldrich, Taufkirchen, 
D 
Akt1, rabbit, monoclo-
nal 
Western blot 
Immunoprecipitation 
1:1000 
10 µl 
Cell Signaling, Frankfurt a. 
M., D 
Akt S473, rabbit, poly-
clonal Western blot 1:500 
Cell Signaling, Frankfurt a. 
M., D 
Akt T308, rabbit, poly-
clonal Western blot 1:500 
Cell Signaling, Frankfurt a. 
M., D 
ATG14, rabbit, polyclo-
nal Western blot 1:500 GeneTex, Irvine, USA 
Beclin-1, rabbit, poly-
clonal 
Western blot 
Immunoprecipitation 
1:1000 
10 µl 
Cell Signaling, Frankfurt a. 
M., D 
Caspase 3, mouse, 
polyclonal Western blot 1:1000 
Cell Signaling, Frankfurt a. 
M., D 
Caspase 8, rabbit, 
monoclonal Western blot 1:1000 
Cell Signaling, Frankfurt a. 
M., D 
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Antibody Application Dilution Company 
Caspase 9, rabbit, pol-
yclonal Western blot 1:1000 
Cell Signaling, Frankfurt a. 
M., D 
DDR1, rabbit, monoclo-
nal 
Western blot 
Immunofluorescence 
1:500 
1:100 
Cell Signaling, Frankfurt a. 
M., D 
DDR1, rabbit, polyclo-
nal Immunoprecipitation 3.5 µg Santa Cruz, Dallas, USA 
DDR1, rabbit, polyclo-
nal 
Immunohistochemis-
try 1:25 GeneTex, Irvine, USA 
DDR1 Y513, rabbit, 
monoclonal Western blot 1:500 
Cell Signaling, Frankfurt a. 
M., D 
GFAP, mouse, mono-
clonal Western blot 1:1000 Millipore, Darmstadt, D 
GST, goat, monoclonal Western blot 1:1000 GE Health Care, Freiburg, D 
LC3b, rabbit, polyclonal 
Western blot 
Immunofluorescence 
1:1000 
1:50 
Cell Signaling, Frankfurt a. 
M., D 
Musashi, rabbit, poly-
clonal Western blot 1:1000 
Cell Signaling, Frankfurt a. 
M., D 
mTOR, rabbit, polyclo-
nal Western blot 1:1000 
Cell Signaling, Frankfurt a. 
M., D 
mTOR S2448, rabbit, 
polyclonal Western blot 1:500 
Cell Signaling, Frankfurt a. 
M., D 
mTOR S2481, rabbit, 
polyclonal Western blot 1:500 
Cell Signaling, Frankfurt a. 
M., D 
Nestin, mouse, mono-
clonal Western blot 1:500 Santa Cruz, Dallas, USA 
Nestin Immunohistochemis-try 1:25 
Sigma Aldrich, Taufkirchen, 
D 
Raptor, rabbit, mono-
clonal Western blot 1:1000 
Cell Signaling, Frankfurt a. 
M., D 
Rictor, rabbit, monoclo-
nal Western blot 1:1000 
Cell Signaling, Frankfurt a. 
M., D 
Sox-2, rabbit, polyclo-
nal Western blot 1:1000 Abcam, Cambridge, UK 
Vps34, rabbit, polyclo-
nal Western blot 1:1000 GeneTex, Irvine, USA 
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4.1.14 Secondary antibodies 
Table 4.11. Secondary antibodies used for Western blot, immunoprecipitation, immunofluorescence or im-
munohistochemical applications. 
Antibody Application Dilution Company 
Anti-mouse IgG, HRP 
conjugated Western blot 1:5000 Pierce, Bonn, D 
Anti-rabbit IgG, HRP 
conjugated Western blot 1:5000 Pierce, Bonn, D 
Anti-mouse IgG, HRP 
conjugated Immunoprecipitation 1:5000 GeneTex, Irvine, USA 
Anti-rabbit IgG, HRP 
conjugated Immunoprecipitation 1:5000 GeneTex, Irvine, USA 
Alexa Fluor®488 
Anti-mouse IgG 
Immunofluores-
cence 
1:200 Life Technologies GmbH, Darmstadt, D 
Alexa Fluor®488 
Anti-rabbit IgG 
Immunofluores-
cence 
1:200 Life Technologies GmbH, Darmstadt, D 
Alexa Fluor®549 
Anti-mouse IgG 
Immunofluores-
cence 
1:200 Life Technologies GmbH, Darmstadt, D 
Alexa Fluor®549 
Anti-rabbit IgG 
Immunofluores-
cence 
1:200 Life Technologies GmbH, Darmstadt, D 
Anti-mouse IgG, HRP 
conjugated Western Blot 1:5000 Pierce, Bonn, D 
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4.1.15 Solutions for cell biological applications 
Table 4.12. Solutions used for cell biological applications. The detailed composition for each solution is 
shown. 
Substance Composition Company 
1x PBS  Sigma Aldrich, Taufkirchen, D 
1x Trypsin/EDTA (4 °C) Sigma Aldrich, Taufkirchen, D 
1% Agarose 
1 g Agarose  
ad 100 ml ddH2O 
Sigma Aldrich, Taufkirchen, D 
10 nM Non-Essential 
Amino Acid Solution 
(NEAA) 
(4 °C) Sigma Aldrich, Taufkirchen, D 
80% Ethanol 800 ml Ethanol, denatured, 99% ad 1 l ddH2O 
Berkel, Berlin, D 
 
B27 supplement (-20 °C) Life Technologies, Karlsruhe, D 
Cell culture medium  
DMEM with GlutaMAX™ 
(supplemented with 10% 
FCS, 1% NEAA) 
BME (supplemented with 
10% FCS, 1% NEAA, 10 
mM Hepes, 2 mM L-gluta-
mine) 
NBM (supplemented with 2 
mM L-glutamine, 32 U/ml 
Heparin, B27 supplement, 
20 ng/ml human EGF and 
20 ng/ml human FGFb) 
(4 °C) 
Life Technologies, Karlsruhe, D 
 
Life Technologies, Karlsruhe, D 
 
 
Life Technologies, Karlsruhe, D 
 
Collagen Type I Rat Tail 
High Concentration  
Corning Life Science, Wiesba-
den, D 
Coomassie stain 
100 ml Methanol 
37,5 ml Acidic acid 
0,25 g Coomassie G250 
ad 500 ml ddH2O 
Roth, Karlsruhe, D 
Merck, Darmstadt, D 
Merck, Darmstadt, D 
 
Fetal Calf Serum (FCS) 
Heat inactivated prior to 
use: 30 min at 56 °C (-20 
°C) 
PAA Laboratories GmbH,  
Cölbe, D 
Heparin 5000U/ml ad 5 ml ddH2O Millipore, Darmstadt, D 
HEPES solution 1M  Sigma Aldrich, Taufkirchen, D 
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Substance Composition Company 
Human EGF 
50 µg reconstituted with 
ddH2O supplemented with 
1% FCS to 200 µg/ml 
Life Technologies, Karlsruhe, D 
Human FGFb lyophilized 
50 µg reconstituted with 
ddH2O supplemented with 
1% FCS to 200 µg/ml 
Life Technologies, Karlsruhe, D 
Lipofektamine2000  Life Technologies, Karlsruhe, D 
LipofectamineLTX  Life Technologies, Karlsruhe, D 
Oligofectamine  Life Technologies, Karlsruhe, D 
OptiMEM with GlutaMAX™ (4 °C) Life Technologies, Karlsruhe, D 
 
4.1.16 Solutions for protein-biochemical and molecular-biological applica-
tions 
Table 4.13. Solutions used for protein-biochemical and molecular-biological applications. The composition 
for each solution is shown. 
Substance Composition Company 
10% Ammonium persul-
fate (APS) 
1 g APS 
ad 10 ml ddH2O (-20 °C) 
AppliChem GmbH, Darmstadt, 
D 
10x Blotting buffer  
(Maniatis-SDS) 
29 g Glycine 
58 g Tris 
ad 1 l ddH2O 
Roth, Karlsruhe, D 
Roth, Karlsruhe, D 
1x Blotting buffer 
100 ml 10x Blotting buffer 
200 ml Methanol 
ad 1 l ddH2O 
Roth, Karlsruhe, D 
 
5% BSA solution 
0,5 g Bovine Serum Albumin  
ad 10 ml PBST (4°C) Serva, Heidelberg, D  
1x Cell Lysis Buffer 
1 ml 10x Cell Lysis Buffer 
40 µl CompleteTM protease in-
hibitor cocktail 
ad 9 ml ddH2O 
Cell Signaling, Frankfurt a. M., 
D 
25x CompleteTM protease 
inhibitor cocktail 
1 Tablet 
ad 2 ml ddH2O (-20 °C) 
Roche Diagnostics GmbH, 
Mannheim, D 
GBX-Developer-Kodak 
250 ml Developer 
ad 1 l ddH2O 
Kodak, Stuttgart, D 
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Substance Composition Company 
GBX-Fixer-Kodak 
250 ml Fixer 
ad 1 l ddH2O 
Kodak, Stuttgart, D 
10x Loading dye 
250 mg Bromphenol blue 
33 ml 150 mM Tris (pH 7,6) 
60 ml Glycerol 
ad 100 ml ddH2O (4°C) 
AppliChem GmbH, Darmstadt, 
D Roth, Karlsruhe, D  
Roth, Karlsruhe, D 
5% Milk powder  
5 g skimmed milk powder 
ad 100 ml 1x PBS (4 °C) 
AppliChem GmbH, Darmstadt, 
D 
Modified RIPA lysis buffer 
951 µl RIPA buffer 
40 µl 25x CompleteTM protease 
inhibitor cocktail 
5 µl 200 mM Na3VO4 
4 µl 500 mM NaF 
 
200 mM Na3VO4 
3,678 g Na3VO4 
ad 100 ml ddH2O (-20 °C) Sigma Aldrich, Taufkirchen, D 
500 mM NaF 
2,1 g NaF 
ad 100 ml ddH2O (-20 °C) Sigma Aldrich, Taufkirchen, D 
20x PBS (pH 7,4) 
160 g NaCl 
4 g KCl 
36 g Na2HPO4 
4,8 g KH2PO4 
ad 1 l ddH2O 
Merck, Darmstadt, D 
Merck, Darmstadt, D 
Merck, Darmstadt, D 
Merck, Darmstadt, D 
1x PBS 
50 ml 20x PBS 
ad 1 l ddH2O 
 
PBS/0,05% Tween 20 
(PBST) 
0,5 ml Tween 20 
ad 1 l 1x PBS 
Serva, Heidelberg, D 
6x Reducing electrophore-
sis loading dye 
5 ml Glycerol 
0,925 g DTT 
1,2 g SDS 
3,5 ml Tris 
1,2 mg Bromophenol blue 
ad 10 ml ddH2O (-20 °C) 
Roth, Karlsruhe, D 
AppliChem GmbH, Darmstadt, 
D 
Roth, Karlsruhe, D 
Roth, Karlsruhe, D 
AppliChem GmbH, Darmstadt, 
D 
RIPA buffer 
12,5 ml Tris-HCl (pH 7,4) 
2,5 ml NP-40 
6,25 ml 10% Sodium deoxy-
cholate 
AppliChem GmbH, Darmstadt, 
D 
Fluka, München, D 
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Substance Composition Company 
7,5 ml 5 M NaCl 
0,5 ml 0,5 M EDTA 
ad 250 ml ddH2O 
(4 °C) 
AppliChem GmbH, Darmstadt, 
D 
Merck, Darmstadt, D 
Roth, Karlsruhe, D 
10% SDS 
100 g SDS 
ad 1 l ddH2O 
Roth, Karlsruhe, D 
10x SDS running buffer 
30,3 g Tris 
144,1 g Glycine 
10 g SDS 
ad 1 l ddH2O 
Roth, Karlsruhe, D 
Roth, Karlsruhe, D 
Roth, Karlsruhe, D 
1x SDS running buffer 
100 ml 10x SDS running buffer 
ad 1 l ddH2O 
 
10x TBE buffer (pH 8,0) 
108 g Tris 
55 g Boric acid 
40 ml 0,5 M Na2EDTA 
ad 1 l ddH2O 
Roth, Karlsruhe, D 
Merck, Darmstadt, D 
Merck, Darmstadt, D 
0,5 M Tris buffer (pH 6,8) 30,275 g Tris 
ad 1 l ddH2O 
Roth, Karlsruhe, D 
3 M Tris buffer (pH 8,8) 181,71 g Tris 
ad 1 l ddH2O 
Roth, Karlsruhe, D 
 
4.1.17 Solutions for immunofluorescence and immunohistological applica-
tions 
Table 4.14. Solutions used for immunofluorescence and immunohistological applications. The composition 
for each solution is shown. 
Substance Composition Company 
0,25% Triton X-100 125 µl Triton X-100 
ad 50 ml 1x PBS 
Roth, Karlsruhe, D 
1% BSA 0,5 g Bovine serum albumin 
(BSA) 
ad 50 ml 1x PBS 
Sigma Aldrich, Taufkir-
chen, D 
3% Formaldehyde 1 ml 37% Formaldehyde  
ad 11 ml 1x PBS 
Merck, Darmstadt, D 
3% Hydrogen peroxide 
(H2O2) 
42,8 ml 35% H2O2 
ad 500 ml ddH2O  
Merck, Darmstadt, D 
IHC work solution 9 ml 110 mM Citric acid 
41 ml 100 mM Sodium acetate 
Merck, Darmstadt, D 
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Substance Composition Company 
ad 500 ml ddH2O 
Hematoxylin  Merck, Darmstadt, D 
1% Eosin solution  Merck, Darmstadt, D 
 
4.1.18 Further solutions and chemicals 
Table 4.15. Further solutions and chemicals used for biochemical, molecular-biological or in vivo applica-
tions.  
Substance Company 
30% Acrylamide bis-acrylamide solution (29:1) Serva, Heidelberg, D 
Agarose, electrophoresis grade Life Technologies, Karlsruhe, D 
Agarose, Type-A Sigma Aldrich, Taufkirchen, D 
Dimethyl sulfoxide (DMSO) AppliChem GmbH, Darmstadt, D 
D-Luziferin Sigma Aldrich, Taufkirchen, D 
Ethanol, denatured, 99% Merck, Darmstadt, D 
Formaldehyde, 37% Merck, Darmstadt, D 
Isopropyl alcohol Merck, Darmstadt, D 
Ketamine Curamed, Karlsruhe, D 
Ponceau S Sigma Aldrich, Taufkirchen, D 
ProLong Diamant Antifade Mountant Life Technologies, Karlsruhe, D 
ProLong Diamant Antifade Mountant with DAPI Life Technologies, Karlsruhe, D 
Red SafeTM nucleic acid staining solution iNtRON Biotechnology, Kyungki-Do, Korea 
Tetramethylethylene-diamine (TEMED) Merck, Darmstadt, D 
Xylazine Curamed, Karlsruhe, D 
 
4.1.19 PC programs 
Table 4.16. PC programs for data analysis and presentation. 
Program Company 
GraphPad Prism 7 GraphPad Software Inc., San Diego, USA 
Fiji (Schindelin et al., 2012) National Institutes of Health 
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Program Company 
Magellan 5.0 Software Tecan, Crailsheim, D 
Microsoft Office 2010 Microsoft Corp., Redmond, WA, USA 
Zeiss LSM Image Browser Version 3,5,0,376 Carl Zeiss GmbH Jena, D 
Zeiss AxioVision SE64 Rel. 4.9 Carl Zeiss GmbH Jena, D 
 
4.2 Methods 
4.2.1 Cell culture 
U343MG, U87MG, A172, LN229 and U138MG human glioblastoma cell lines were ob-
tained from American Type Culture Collection (ATCC). Human Glioblastoma cell lines 
DD-HT7607 and DD-T4 were kindly provided by A. Temme (University Hospital Dresden, 
Germany). Human HEK293T cells were kindly provided by A. Dubrovska (University 
Hospital Dresden, Germany). Cells were cultured in Dulbecco's modified Eagle's medium 
(DMEM) supplemented with 10 % fetal calf serum and 1 % non-essential amino acids at 
37 °C in a humidified atmosphere containing 8.5 % CO2. U343MG cells were cultured in 
Basal Medium Eagle (BME), supplemented with 10 % fetal calf serum, 10 mM Hepes, 
2 mM L-glutamine, and 1 % non-essential amino acids at 37 °C in a humidified atmos-
phere containing 5 % CO2. Cells were grown to 70 % confluency and harvested or sub-
cultured every 3-4 days. Human GBM stem-like cells GS-8 and GS-5 (Günther et al., 
2008) were kindly provided by K. Lamszus (University Medical Center Hamburg-Eppen-
dorf, Germany) via material transfer agreement. Human DK32, DK41 and DK42 were 
isolated as described (Vehlow et al., 2017). GS-5, GS-8, DK32, DK41 and DK42 were 
grown in Neurobasal Medium (NBM) supplemented with 2 mM L-glutamine, 32 U/ml 
Heparin, B27 supplement, 20 ng/ml human EGF and 20 ng/ml human FGFb at 37 °C 
and 5 % CO2. GS-8_GFP/fLuc cells were generated by lentiviral transduction of 
p6NST50 containing EGFP and firefly luciferase genes as described (Vehlow, 2017). To 
subculture non-adherent GSC cultures, cells were harvested and centrifuged at 130 g 
for 3 min. The supernatant was removed, a single cell suspension was produced by me-
chanical dissociation using a 100 µl pipette and cells were resuspended in fresh culture 
medium. Subsequently, cells were transferred to a new cell culture flask. 
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4.2.2 Cell freezing and thawing 
Cells for freezing were cultured in T-175 flasks. Adherently growing cells were tryp-
sinised, resuspended in culture medium and transferred to 15 ml centrifuge tubes. Sub-
sequently, cells were centrifuged at 130 g for 3 min and resuspended in 6 ml freezing 
medium (complete DMEM supplemented with 20 % FCS and 0.5 % DMSO). One millili-
tre suspension was transferred to each cryo-vial. Cells were placed into a freezing con-
tainer and cooled down slowly to -80 °C. Cell stocks were stored at -150 °C. For freezing 
of GBM stem-like cultures, cells were harvested and centrifuged at 130 g for 3 min. The 
supernatant was removed, a single cell suspension was produced using a 100 µl pipette. 
Cells were resuspended in freezing medium (NBM supplemented with 0.5 % DMSO). 
For thawing, cells were rapidly resuspended in culture medium. Cells were centri-
fuged at 130 g for 3 min, resuspended in 5 ml fresh culture medium and cultured in a T-
25 flask under standard cell culture conditions. 
4.2.3 siRNA knockdown 
RNA interference holds the possibility to specifically inhibit the expression of target pro-
teins (Elbashir et al., 2001; Kim, 2005). Using small interfering RNAs (siRNAs), the ex-
pression of the proteins Akt1, Beclin-1, DDR1 as well as the mTOR subunits Raptor and 
Rictor were knocked down (Table 4.3). For transfection, 3 x 105 cells in 2 ml medium or 
1.2 x 106 cell in 10 ml medium were plated in 6-well plates or 100 mm dishes, respec-
tively. Twenty-four hours after cell seeding, cells were transfected using 20 nM siRNA. 
Nonspecific control siRNA (siC) or specific siRNA were diluted in OpitMEM. In parallel, 
an Oligofectamine/ OptiMEM dilution was prepared using a different reaction tube (Table 
4.17). Both dilutions were incubated for 10 min. Subsequently, the siRNA and the Oligo-
fectamine dilutions were mixed and the resulting solution was incubated for additional 20 
min. in parallel, cells were washed with OptiMEM. Finally, 800 µl or 4.8 ml OptiMEM were 
added per 6-well or 100 mm dish, respectively. Transfection of cells was performed using 
200 µl (6-well) or 1.2 ml (100 mm dish) transfection mix. Following an 8 h incubation pe-
riod under standard cell culture conditions, OptiMEM supplemented with 20 % FCS was 
added (1 ml per 6-well or 6 ml per 100 mm dish). Twenty-four hours after transfection, 
cells were seeded for experiments.  
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Table 4.17.Pipetting scheme for siRNA transfection in 6-well plates and 100 mm dishes. 
   siRNA dilution Oligofectamine dilution 
 csiRNA cfinal siRNA Opti-MEM 
Oligofec-
tamine OptiMEM 
6-well 
plate 20 mM 20 nM 1 µl 184 µl 4 µl 11 µl 
100 mm 
dish 20 mM 20 nM 6 µl 1104 µl 24 µl 66 µl 
 
4.2.4 Inhibitor treatment and chemotherapy 
The chemotherapeutic agent Temozolomide and the specific DDR1-IN-1 inhibitor DDR1-
IN-1 were used for in vitro as well as in vivo experiments as single compounds or in 
combination prior to X-ray irradiation. For cell culture experiments the compounds were 
diluted in DMSO. Specific EC10 and EC50 concentrations for each cell line were deter-
mined using either the colony formation assay for adherent cell lines or the sphere for-
mation assay for GSC cultures. For animal experiments compounds were diluted in 
0.9 % NaCl solution. Concentrations of 25 mg/kg DDR1-IN-1 and 22 mg/kg TMZ were 
used for single injections. While substances were applied 1 h prior to irradiation when 
applied in cell culture experiments, intraperitoneal injection of the compounds was per-
formed 3 h prior to X-ray treatment in animal experiments. 
 
4.2.5 Radiation exposure 
In vitro and in vivo X-ray irradiation was delivered at room temperature using single 
doses of 200 kV X-rays filtered with 0.5 mm Cu (Yxlon Y.TU 320; Yxlon, Hamburg, Ger-
many). The dose-rate was approximately 1.3 Gy/min at 20 mA. The absorbed dose was 
measured using a Duplex dosimeter (PTW, Freiburg, Germany). Applied doses ranged 
from 0 to 6 Gy X-rays. 
 
4.2.6 Colony formation assay 
Effects of genotoxic stress induced by ionizing radiation or cytotoxic substances can be 
analysed using the colony formation assay. This assay is the gold standard in radiobiol-
ogy to measure the reproductive integrity of cells (Puck and Marcus, 1956). Cells that 
are able to pass through five or more mitoses and form colonies of at least 50 cells are 
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considered clonogenic since they have retained their capacity to divide indefinitely (van 
der Kogel, 2009). An important parameter for the analysis of this assay is the plating 
efficiency (PE). This term refers to the percentage of seeded cells that grow into colonies 
and thereby reflects the basal cell survival (Hall and Giaccia, 2012). Upon irradiation or 
treatment with cytotoxic substances the fraction of surviving cells (SF) is calculated using 
the formula below: 
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The results are presented as dose survival curves showing mean ± s.e.m., with the dose 
plotted on a linear scale and surviving fraction on a logarithmic scale (Puck and Marcus, 
1956). 
Measurement of clonogenicity was performed by plating single cells (U87MG, 
A172, LN229, U138MG, DD-HT7606, DD-T4 and U343MG) in collagen type I coated 
(1 µg/cm2) 6-well culture dishes as published (Cordes et al., 2003). For each cell line a 
specific cell number per 6-well was defined and seeded in a total of 2 ml culture medium. 
Cells were incubated at standard cell culture conditions (section 4.2.1) for 24 h. 
Table 4.18. Cell numbers and corresponding incubation periods used for colony formation assays. Cell 
numbers and incubation times were adjusted individually for each cell line and condition. 
 Cell numbers  
Cell line 0 Gy 2 Gy 4 Gy 6 Gy Incubation [d] 
U87MG 1000 1000 2000 4000 15 
A172 1000 1000 2000 4000 15 
LN229 600 600 1200 2400 10 
U138MG 1000 1000 1200 2400 15 
DD-HT7606 1000 1000 2000 4000 12 
DD-T4 1000 1000 2000 4000 10 
U343MG 600 600 1200 2400 10 
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Cells were treated with DDR1-IN-1, Temozolomide and combinations (DMSO as control) 
for 24 h and then washed with 1x PBS. Cells were irradiated 1 h after addition of inhibitor 
or TMZ with 2, 4 and 6 Gy single doses or left unirradiated. After cell line specific incu-
bation periods at standard culture conditions cells were fixed for 10 min using 80 % eth-
anol and stained for 30 min with Coomassie stain. Next, wells were washed with tap 
water and allowed to air dry. Each well was analysed counting colonies of at least 50 
cells using the binocular microscope.  
 
4.2.7 Sphere formation assay 
The sphere formation assay offers the possibility to measure the reproductive integrity 
of non-adherent GSC cultures. Similar to the colony formation assay, cells that are able 
to pass through five or more mitoses and form spheres under non-adherent stem cell 
culture conditions are considered to be clonogenic. Spheres of at least 100 µm diameter 
were counted. The sphere formation capacity is calculated for basal cell survival (without 
irradiation) and survival upon 2-6 Gy X-rays. The results are presented as dose survival 
curves showing mean ± s.e.m., with the dose plotted on a linear scale and surviving frac-
tion on a logarithmic scale.  
Sphere formation capacity was assessed by plating 300,000 cells (GS-5, GS-8, 
DK32, DK41, DK42) in 24-well culture dishes. Two hours after incubation at 37 °C and 
5 % CO2, cells were treated with either DDR1-IN-1, TMZ or combinations (DMSO as 
control). One hour after treatment, cells were irradiated with 2, 4 and 6 Gy single doses 
or left unirradiated. Following 24 h of incubation under standard cell culture conditions, 
cells were harvested and centrifuged at 130 g for 3 min. The supernatant was removed, 
a single cell suspension was produced using a 100 µl pipette and 2000 cells per well 
were plated in 96-well plates. After 5 days of incubation at 37 °C and 5 % CO2, sphere 
formation assays were stopped with 3 % Formaldehyde, spheres >100 µm were micro-
scopically counted. 
 
4.2.8 Invasion Assay 
To analyse the invasive capacity of cells in a three-dimensional ECM-rich environment, 
GBM cells grown as spheroids were placed in a collagen type I matrix and the distance 
of cells invading out of the spheroid into the surrounding collagen gel was determined. 
In detail, 10,000 cells/ well were seeded into agarose coated 96-well round bottom plates 
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(50 µl 1 % agarose/ well) and allowed to form spheroids for 48 h at 37 °C and 5 % CO2. 
Twenty-four-well plates were coated with 250 µl 1 % agarose/ well. A 1 mg/ml collagen 
type I matrix, which was prepared as described in Table 4.19 and 500 µl/ well were trans-
ferred to agarose coated 24-well plates. Compact spheroids were picked using a 100 µl 
pipette and placed into the freshly prepared collagen matrix. After solidification of the 
collagen gel at 37 °C and 5 % CO2 for 2 h, gels were covered with 200 µl culture medium 
and cells were microscopically monitored thereof every 24 h for 72 h. 
Table 4.19. Pipetting scheme for 1 ml collagen type I solution for the invasion assay. 
Reagent Volume 
10x Hank’s Buffered Salt Solution 100 µl 
1 M NaOH solution 2.4 µl 
Collagen type I stock solution 
(9.67 mg/ml) 
103 µl 
Culture medium ad 1 ml 
 
4.2.9 Total protein extracts, SDS-PAGE and Western Blotting 
4.2.9.1 Cell lysates 
For cell lysates of adherent cell cultures, 1.2 x 106 cells in 10 ml culture medium were 
seeded into 100 mm dishes (coated with 1 µg/m2 collagen type I where indicated) and 
incubated for 24 h at standard culture conditions. Cell lysis was performed on ice. Cells 
were washed with 2 ml ice cold 1x PBS. Next, 200 µl modified RIPA lysis buffer were 
added to the dish and cells were detached using a cell scraper. Non-adhered GSC cul-
tures were harvested and centrifuged at 130 g for 3 min. Subsequently, the supernatant 
was removed and cells were lysed with 200 µl modified RIPA lysis buffer. The lysate was 
transferred to a 1.5 ml reaction tube and incubated on ice for 30 min. Following incuba-
tion, the lysate was resuspended using an insulin syringe, incubated for 1 h on ice and 
centrifuged for 20 min at 16,000 g and 4 °C. The supernatant was removed and trans-
ferred to a new 1.5 ml reaction tube. The protein concentration was determined using 
96-well plates and the BCA Protein Assay Kit (Hehlgans et al., 2009). Lysates were di-
luted 1:10 in RIPA buffer and a BSA concentration series (0.0 µg/µl – 2.0 µg/µl) was pre-
pared. Next, BCA reagent was added according to the manufacturer’s instructions and 
samples were incubated at 37 °C for 30 min. Using a microplate reader together with the 
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Magelan 5.0 software the absorption of standard series and samples was measured and 
the protein concentration was calculated. 
4.2.9.2 SDS-Polyacrylamide gel electrophoresis (SDS-PAGE) 
SDS-PAGE, developed by Laemmli (1970), is used to separate proteins of a whole cell 
lysate according to molecular weight of the single proteins. Gels for SDS-PAGE were 
prepared using the Hoefer Mini gel system. Based on the molecular weight of the target 
proteins, different separation gels with varying acryl amid concentrations (4 %, 8 %, 10 % 
and 12 %) were prepared (Table 4.20). For all separations, 5 % stacking gels were used. 
Stacking and separation gels were prepared on ice. 
Lysates were mixed 1:6 with 6x loading dye and denaturated at 99 °C for 5 min. 
Gels were loaded with 25 µg protein lysate per sample. As protein ladder 5 µl PageRuler 
Unstained were applied. Electrophoresis was carried out using a current of 25 mA per 
gel. 
Table 4.20. Composition of stacking and separation gels used for SDS PAGE.  
Stacking gel 5 % [ml] 
Separation 
gel 
4 % 
 [ml] 
8 % 
 [ml] 
10 % 
[ml] 
12 % 
[ml] 
ddH2O 1,63 ddH2O 2,83 2,16 1,83 1,5 
0,5 M Tris/HCL 
pH 6,8 0,72 
3 M Tris/HCL 
pH 8,8 1,25 1,25 1,25 1,25 
Acryl amide 30 
% 0,5 
Acryl amide 30 
% 0,67 1,33 1,67 2,00 
50 % Glycerol 0,06 50 % Glycerol 0,10 0,10 0,10 0,10 
10 % SDS 0,03 10 % SDS 0,05 0,05 0,05 0,05 
10 % APS 0,06 10 % APS 0,10 0,10 0,10 0,10 
TEMED 0,0048 TEMED 0,004 0,004 0,004 0,004 
 
4.2.9.3 Western Blot 
Transfer of the electrophoretically separated proteins onto a nitrocellulose membrane 
was performed using a semi dry blotter. In detail, the stacking gel was removed and 6 
sheets of Whatman paper as well as one sheet nitrocellulose membrane soaked with 1x 
blotting buffer were assembled as depicted in Figure 4.1. Proteins were transferred for 
2.5 h using a current of 0.8 mA/cm2 membrane. Following transfer, proteins were stained 
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with PonceauS solution and membranes were cut according to the size of target proteins. 
Subsequently, membranes were destained in 1x PBS and blocked for 1 h in 5 % milk 
powder or 5 % BSA solution according to the instructions of antibody manufacturers.  
After blocking, membranes were incubated with primary antibodies over night at 4 °C. 
Membranes were washed 4x for 10 min in PBST prior to incubation with secondary an-
tibodies for 1.5 h at RT. Next, membranes were washed in PBST (5 x 10 min) and PBS 
(1 x 10 min) and incubated for 5 min with the ECL Western Blotting Detection system. 
Proteins were detected using X-ray films. 
 
4.2.9.4 Analysis of protein expression and phosphorylation 
To quantify the expression of total or phosphorylated proteins, X-ray films were scanned 
and densitometric analysis was performed using Fiji. Protein band intensity was quanti-
fied and normalised to either β-Actin (for total protein) or total protein expression (for 
analysis of phosphorylations). 
 
4.2.10 Orthotopic mouse model 
To investigate the radiosensitising potential of DDR1 inhibition and a combined 
DDR1/TMZ regimen in a model system more accurately reflecting physiological condi-
tions, an orthotopic glioblastoma mouse model was applied. For this type of in vivo 
model, tumour cells are implanted into their organ of origin to provide an organ-specific 
microenvironment and therefore ensure more physiological conditions for tumour growth. 
For these experiments, GS-8 cells expressing GFP and firefly luciferase were used. GS-
8_GFP/fLuc tumours show an invasive phenotype with pronounced necrosis in tumour 
Figure 4.1. Scheme of the Western blot setup. Whatman paper and nitrocellulose membrane were 
soaked with 1x blotting buffer. Three sheets of Whatman paper were placed on the anode and covered with 
the nitrocellulose membrane followed by the gel. Finally, 3 sheets of Whatman paper and the cathode were 
placed on top. 
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core regions and thereby closely mimic the pathology of human glioblastomas (Vehlow 
et al., 2017).  
For in vivo experiments, 10 to 12-week-old male and female athymic nude mice 
(NMRI nu/nu) were obtained from the OncoRay animal facility, Medical Faculty Carl Gus-
tav Carus, Technische Universität Dresden, Germany. Mice were anesthetised using 
10 mg/kg body weight (BW) xylazine and 100 mg/kg BW ketamine. Anaesthetics were 
injected intraperitoneal (i.p.) and the amount of injected substance was based on guide 
lines of the animal welfare committee.  
For orthotopic transplantation of GS-8_GFP/fLuc cells the scalp of the mice was 
incised at the midline and a 0.5 mm hole was drilled into the cranial bone of the right 
hemisphere. Subsequently, 25,000 GS-8_GFP/fLuc cells in 3 µl PBS were orthotopically 
transplanted using a stereotactic device. Six days after intracranial injection, mice were 
injected with 150 mg/kg BW D-Luciferin (i.p.) and tumour growth was measured using 
the IVIS system. Mice with engrafted tumours were randomly assigned to different treat-
ment groups and treated for 3 cycles (on 3 consecutive days) with 25 mg/kg BW DDR1-
IN-1, 22 mg/kg BW TMZ, a combination or corresponding amount of NaCl as control. X-
ray irradiation (4 Gy) commenced 3 h after treatment under anaesthesia (Figure 4.2). To 
do this, a special collimator plate designed to precisely irradiate the head of the mice 
while sparing the eyes, snout and rest of the body was used. Tumour growth was as-
sessed twice weekly by luminescence imaging as described above.  
 Animals with a declining condition were euthanized in accordance to the local 
guidelines and the whole brain was immediately collected for histological analysis. As-
sessment of the health condition of the mice was done in cooperation with the animal 
welfare officer of OncoRay and the Medical Faculty Carl Gustav Carus, Technische Uni-
versität Dresden, Germany. Animal facilities and experiments were authorised by the 
Regierungsministerium Dresden Germany, according to the German and Saxony animal 
welfare regulations (No. TVV 57/2015).  
Figure 4.2. Treatment scheme for mice bearing orthotopic GS-8_GFP/fLuc tumours. Six days after 
orthotopic transplantation mice received 3 cycles of 25 mg/kg BW DDR1-IN-1, 22 mg/kg BW TMZ or a 
combination 3 h prior to 4 Gy X-irradiation. Tumor growth was monitored thereof based on luminescence.  
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Before, during and after treatment, animals were housed in the special pathogen-
free facility of the OncoRay – National Center for Radiation Research in Oncology, Tech-
nische Universität Dresden, Germany. A constant temperature of 26°C, a 12 h light – 
12 h dark electric cycle, water ad libitum and a commercial laboratory animal diet were 
provided for the animals. 
 
4.2.11 Histology and immunohistochemistry 
Immunohistochemistry on sections of paraffin-embedded patient material was performed 
by Ricarda Hannen, Maria Hauswald and Jörg-Walter Bartsch (Universität Marburg Ger-
many) using antibodies against DDR1 and Nestin. Images were obtained using the LSM 
700 confocal microscope (Zeiss) with a 63x 1.4 NA oil immersion objective. Image pro-
cessing was performed with Fiji. For analysis of DDR1 and Nestin staining intensities, 
cells were localised and marked using the DAPI channel. Subsequently, the DDR1 and 
Nestin signal intensities were measured for each individual cell and correlated using 
GraphPad Prism 7. For immunohistochemical analysis tumour specimens were fixed in 
4 % formaldehyde overnight and embedded in paraffin. Prior to immunohistochemical 
staining, specimens were deparaffinised using xylene (3x 10 min) and different ethanol 
dilutions (2x 100 %, 90 %, 80 %, 70 % and 40 % for 3 min each) followed by a PBS 
washing step (1 min). The deparaffinised tumour specimen was subsequently trans-
ferred to IHC work solution and heated to 100 °C for 25 min using a microwave. After 
heating the samples, microscopy slides were allowed to air dry and specimens were 
encircled using a grease pencil. Tumour nuclei as well as cytoplasm, collagens, keratins 
and erythrocytes were stained using hematoxylin and eosin G (Table 4.14). Specimens 
were incubated in Mayer’s hemalaun solution (Table 4.14) for 3 min and subsequently 
rinsed with tap water for 5 min. Next, the tumour sample was incubated in 1 % eosin 
solution for 3-min. For immunofluorescence analysis, sections were incubated with spe-
cific primary antibodies. For tyramide based immunofluorescence detection, the TSA-kit 
was used according to the manufacturer’s instructions. Sections were mounted using 
ProLong Diamant Antifade Mountant with DAPI for nuclear counterstaining. Images were 
acquired using an AxioImager M1 microscope or LSM510meta. 
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4.2.12 Phosphoproteome analysis 
To analyse the expression of 342 proteins and 606 phospho-sites 1 h post DDR1-IN-1 
treatment the Phospho Explorer Antibody Microarray was conducted by Full Moon Bio-
Systems Inc. as published (Eke et al., 2015; Vehlow et al., 2017). Whole cell lysates from 
4.5 x 106 U343MG cells plated on collagen type I were harvested 1 h after treatment with 
DDR1-IN-1 (EC50) or DMSO. Protein extracts were prepared as described in section 
4.2.9.1 and transferred to Full Moon BioSystems Inc. on dry ice. At Full Moon BioSys-
tems Inc. proteins were labelled with biotin and placed on preblocked microarray slides. 
Detection of total and phosphorylated proteins was conducted using Cy3-conjugated 
streptavidin. Expression of phosphorylated proteins was normalised to the correspond-
ing total protein expression. Proteins with phosphorylation site changes of at least 30 % 
reduction or 50 % enhancement were selected and classified for functionality according 
to their membership in known signalling pathways (PANTHER pathways) using www.ge-
neontology.org (Ashburner et al., 2000). To visualise the molecular interaction network 
of Akt and mTOR the Cytoscape program (Cytoscape Consortium (Christmas et al. 
2005)) was used and proteins regulated upon DDR1 inhibition were marked. 
 
4.2.13 Immunoprecipitation 
Immunoprecipitation is a well-established and widely used technique for the detection 
and analysis of protein-protein interactions. The method is based on precipitating an an-
tibody-protein complex out of a cell lysate by using protein A/G-beads. By subsequent 
SDS-PAGE and Western blotting, proteins bound to a protein of interest can be detected 
or precipitates may be subjected to mass spectrometry analysis.  
For analysis of endogenous protein-protein interactions, 150 mm dishes of 
U343MG and GS-8 cells were used to generate whole cell lysates. Cells were harvested 
using 10x cell lysis buffer (Cell Signaling) diluted 1:10 with ddH2O and supplemented 
with 40 µl/ml Complete protease inhibitor cocktail. The total protein amount was meas-
ured by BCA assay. Cell lysates were pre-cleared using 150 μl of a Protein A/G se-
pharose slurry (50 % v/v). To do this, the lysate-bead solution was rotated at 4 °C for 1 h 
using a laboratory rotator. Following pre-clearing, lysates were centrifuged at 500 g for 
5 min and the supernatant was transferred to a new reaction tube. Primary antibodies 
(IgG as isotype control) were added to 1.5 mg protein lysate and rotated for 1 h at 4 °C. 
Subsequently, 150 μl of a Protein A/G sepharose slurry (50 % v/v) was added and ro-
tated overnight at 4 °C. Immunoprecipitates were washed 3 times with cold lysis buffer. 
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Whole cell lysates and immunoprecipitated proteins were boiled in 50 μl sample buffer, 
separated by SDS-PAGE, transferred, and blotted. Protein precipitates were analysed 
with specific primary antibodies as indicated. 
4.2.14 Mass spectrometric analysis 
Mass spectrometry is a technique to analyse masses of molecules and atoms. The sam-
ple is transferred to the gas phase and ionized. The ions are accelerated by an electric 
field and loaded into the analysis unit of the mass spectrometer. Within the spectrometer 
the ions are sorted according to the mass to charge ratio, which allows identification of 
interacting proteins. Following immunoprecipitation, mass spectrometry offers the oppor-
tunity to determine the set of proteins bound to a certain protein of interest (Eke et al., 
2010; Eke et al., 2012).  
All required solutions for immunoprecipitation and SDS-PAGE were prepared from 
freshly opened reagents under sterile and inert conditions. Bottles and beakers to pre-
pare the solutions as well as the equipment for SDS-PAGE were cleaned using 1 M HCl, 
1 M NaOH and 1 % SDS solutions. After DDR1 immunoprecipitation (IgG as isotype 
control) protein mixtures were separated via SDS-PAGE. The gel was Coomassie 
stained to ensure DDR1 precipitation, destained and placed into a 100-mm dish. The gel 
was covered with Coomassie destain and transferred to the Mass spectrometry core 
facility of the Max Planck Institute of Cell Biology and Genetics, Dresden for analysis.  
Here, the separated proteins were in-gel digested with trypsin and peptides, recov-
ered from the gel matrix and analysed on a LTQ Orbitrap XL mass spectrometer (Thermo 
Fischer Scientific) coupled on-line to Ultima3000 LC system (Dionex) via a TriVersa ro-
botic ion source (Advion BioScience) as described (Shevchenko et al., 2008). Database 
searches were performed by MASCOT software (Matrix Science) against HumanIPI da-
tabase under following settings: mass accuracy 20 ppm and 0.5 Da for precursor and 
fragment ions correspondingly; enzyme specificity – Trypsin; variable modifications: Me-
thionine oxidated, Cysteine propionamide. Protein hits were then evaluated using Scaf-
fold software (Proteome Software) under following settings: minimal peptide probability 
95 %, minimal protein probability 99 %, and minimal number of matched peptides. Bio-
informatic analysis of detected proteins was carried out using the DAVID gene ontology 
database (Huang et al., 2009). 
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4.2.15 Expression constructs, site-directed mutagenesis and transfection 
of plasmids 
4.2.15.1 PCR  
Fluorescent or GST-fusion proteins were generated by PCR amplification (Table 4.21) 
of a gene of interest with simultaneous addition of appropriate restriction sites, restriction 
digest of PCR product and desired expression vector (Table 4.22) followed by ligation.  
A list of the used primers is provided in Table 4.7. PCR products were purified 
using the NucleoSpin® Gel and PCR cleanup kit according to the manufacturer’s instruc-
tions.  
Table 4.21: PCR protocol used to amplify genes of interest and add flanking restriction sites. 
Reagent Required concentration Amount per PCR tube 
PCR buffer (10x) 1x 5 µl 
dNTP 10 mM 1 µl 
ForwardPrimer 10 μM 1 µl 
Reverse Primer 10 μM 1 µl 
MgCl2 25 mM 1.25 µl 
HotStar Plus Polymer-
ase 
5 units/μl 0.25 µl 
cDNA 500 ng/µl Plasmid dependent 
H2O  Ad 50 µl 
 
Human DDR1b was generated by PCR-based amplification from expression plasmids, 
with specific primers (DDR1_pmCherry_F_238 and DDR1_pmCherry_R_239). Con-
structs were flanked with Kpn I and Bam HI restriction sites and inserted into the Kpn I 
and Bam HI sites of pmCherry-N1 (DDR1WT-mCherry). 
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Table 4.22. Protocol for restriction digest of PCR-products flanked with restriction sites and desired ex-
pression vectors. High fidelity restriction enzymes (NEB, Frankfurt a.M., D) were applied. 
Reagent Volume 
Purified PCR product 30 µl 
Vector 10 µg Vector dependent 
CutSmart 10 µl 
Enzyme I 3.5 µl 
Enzyme II 3.5 µl 
ddH2O ad 100 µl 
 
The expression vector pGST-N1 was generated by PCR-based amplification of GST 
from pGEX-6P-1 expression plasmids with specific primers (GST-AgeI_F_280 and GST-
XbaI_R_281). Constructs were flanked with Age I and XbaI restriction sites and inserted 
into the Age I and XbaI sites of pmCherry-N1 to simultaneously cleave out mCherry and 
insert GST.  
DDR1-GST expression vectors were generated by PCR-based amplification from 
DDR1WT-mCherry with specific primers (DDR1WT-NheI-F-100 and DDR1WT-KpnI-R-
101). Constructs were flanked with Nhe I and Kpn I restriction sites and inserted into the 
Nhe I and Kpn I sites of pGST-N1. Truncated DDR1 constructs (DDR1∆KD, DDR1∆ICD) 
were generated by PCR-based amplification from DDR1WT-mCherry plasmids with spe-
cific primers (DDR1WT-NheI-F-100, DDR1∆KD-KpnI-R-102, and DDR1∆ICD-KpnI-R-
103) using the aforementioned cloning strategy. Putative 14-3-3 binding motifs in DDR1 
were determined using the GPS kinase prediction tool (Xue et al., 2005; Xue et al., 2008).  
Human YWHAQ (14-3-3 theta) was generated by PCR-based amplification from 
fresh placenta cDNA with specific primers (14-3-3WT-F-111 and 14-3-3WT-R-112). Con-
structs were flanked with Bgl II and Sal I restriction sites and inserted into the Bgl II and 
Sal I sites of pEGFP-N1. 
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Table 4.23. Protocol for ligation of PCR-products flanked with restriction sites and desired expression vec-
tors. The NEB cloner/Ligation calculator was used to calculate the amount of purified PCR product necessary 
to achieve a vector:insert ratio of 1:3 or 1:5. 
Reagent Self-ligation control Amount per PCR tube 
1:3 1:5 
Purified Vector 1 μl 1 μl 1 μl 
Purified PCR product 0 μl Dependent on size of PCR prod-
uct and vector (calculated with 
NEB cloner) 
Ligation Buffer 2 μl 2 μl 2 μl 
T4 DNA Ligase  1 μl 1 μl 1 μl 
ddH2O 16 μl ad 20 μl ad 20 μl 
    
4.2.15.2 Transformation 
Plasmid transformation into competent DH5α E.coli (NEB, Frankfurt a.M., D) was per-
formed using heat shock. In detail, 50 µl competent cells were thawed and incubated 
with 2 µl plasmid DNA for 30 min on ice. Subsequently, bacteria were heated to 45 °C 
for 42 s followed by 2 min incubation on ice. After transformation, 950 µl SOC medium 
was added and bacteria were incubated for 2 h at 500 rpm and 37 °C using a thermo-
mixer. Next, 200 µl bacteria suspension were seeded in agar plates containing either 
Ampicillin or Kanamycin for selection of successfully transformed clones. After 24 h in-
cubation at 37 °C, positive clones were picked. Each clone was transferred to a 15-ml 
centrifuge tube containing 5 ml selection medium and incubated for 6 h at 37 °C using a 
bacterial shaker. Subsequently, 4 ml of the pre-culture were added to 200 ml selection 
medium and incubated overnight at 37 °C using a rotary shaker. Plasmid DNA was iso-
lated using the NucleoSpin® Plasmid EasyPure kit according to the manufacturer’s in-
structions and correct integration of the insert-DNA into the desired vector was verified 
by sequencing. 
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4.2.15.3 Site-directed mutagenesis 
Mutation of the putative 14-3-3 binding sites (S448A and S889A) was performed using 
the QuikChange II Site-Directed Mutagenesis Kit according to manufacturer’s instruc-
tions with specific primers (pGST-DDR1-1341-F-106, pGST-DDR1-1341-R-107, pGST-
DDR1-2664-F-108 and pGST-DDR1-2664-R-109 (Table 4.7). Putative 14-3-3 binding 
sites were modified by mutation of serine residues to alanine in the supposed 14-3-3 
binding motifs of DDR1 (DDR1S448A, DDR1S889A, DDR1AA). Plasmids with mutated 
DDR1 variants were transformed as described in section 4.2.15.2 and correctness of the 
mutated sites was confirmed by sequencing. 
 
4.2.15.4 Plasmid transfection 
Cells were transiently transfected with 1 µg pmCherry-N1, DDR1WT-mCherry, pGST-
N1, DDR1WT-GST, DDR1∆KD-GST, DDR1∆ICD-GST, DDR1S448A-GST, 
DDR1S889A-GST, DDR1AA-GST, pEGFP-N1, 14-3-3-EGFP using 6-well plates and 
Lipofectamine LTX according to the manufacturer’s instructions. 
 
4.2.16 GST-Pulldown 
Glutathione-S-transferase (GST) is an enzyme that shows high affinity to glutathione. 
This interaction can be used to purify proteins of interest from a whole cell lysate in a 
process called GST-pulldown assay. Therefore, a protein of interest is tagged with GST 
and expressed in mammalian cells. Due to binding of GST to glutathione, the GST-fusion 
protein and proteins bound to it can be separated using glutathione coated beads. This 
technique can be used to elucidate direct protein–protein interactions.  
For GST-pulldown, 1.2 million HEK293T cells were seeded in a 100-mm dish. 
Twenty-four hours after cell seeding, HEK293T cells were transiently transfected with 
10 µg plasmid DNA (pGST-N1, DDR1WT-GST, DDR1∆KD-GST, DDR1∆ICD-GST, 
DDR1S448A-GST, DDR1S889A-GST, DDR1AA-GST) using Lipofectamine LTX accord-
ing to the manufacturer’s instructions. Cells were harvested 48 h after transfection for 
co-precipitation assays. For cell harvesting 10x cell lysis buffer (Cell signaling) was di-
luted 1:10 with ddH2O and supplemented with 40 µl/ml Complete protease inhibitor cock-
tail. Total protein amount was measured by BCA assay. 150 μl glutathione-sepharose 
beads (50 % slurry) were added to the cell lysate and rotated overnight at 4°C. GST-
pulldowns were washed 3 times with ice cold lysis buffer. Whole cell lysates and 
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precipitated proteins were boiled in 50 μl sample buffer, separated by SDS-PAGE, trans-
ferred, and blotted. Protein precipitates were analysed with specific primary antibodies 
as indicated. 
 
4.2.17 Fluorescence microscopy 
Immunofluorescence is a technique to visualise the localisation of proteins of interest 
based on the specificity of antibody-antigen interactions. A primary antibody is used to 
specifically bind a protein of interest and a fluorophore-coupled secondary antibody di-
rected against the primary antibody is used for detection. Using a fluorescence micro-
scope or a laser scanning microscope the localisation of the protein can be visualised. 
To analyse endogenous localisation of DDR1 in GBM cell lines, 50 x 105 GBM cells 
were grown on collagen type I (1 µg/cm2) coated coverslips. Twenty-four hours after cell 
seeding cells were fixed with 3 % Formaldehyde. GS-8 and DK41 GSCs were centri-
fuged at 130 g for 3 min, the supernatant was removed, and cells were fixed with 3 % 
Formaldehyde. Subsequently, cells were washed 3 times with ice cold 1x PBS and 
treated with 0.25% Triton-X-100/PBS for 5 min followed by three 1x PBS washing steps. 
Cells were blocked using 1 % BSA/PBST for 30 min. Specific primary antibodies were 
incubated for 2 h at room temperature. Subsequently, specific primary antibodies were 
washed off using 3 times 1x PBS and cells were incubated with fluorophore-coupled 
secondary antibodies or fluorophore-coupled-Phalloidin (for F-actin staining) for 1 h. Fol-
lowing incubation, cells were washed with 1x PBS and mounted using ProLong Diamant 
Antifade Mountant with DAPI. To determine DDR1/14-3-3 complexation and complex 
disassembly upon DDR1 inhibition, HT7606 cells grown on collagen type I (1 µg/cm2) 
were treated with DDR1-IN-1 (EC50) 1 h prior to fixation with 3 % Formaldehyde (DMSO 
as control). Staining of proteins was accomplished with specific antibodies: Subse-
quently, samples were incubated with fluorophore-coupled secondary antibodies for 1 h 
and mounted using ProLong Diamant Antifade Mountant with DAPI. Images were ac-
quired using LSM510meta (Zeiss). 
 
4.2.18 Fluorescence Resonance Energy Transfer (FRET) analysis 
To microscopically investigate direct protein-protein interactions, FRET microscopy can 
be used. Fluorescence resonance energy transfer, when applied to optical microscopy, 
allows determination of interactions between two proteins within several nanometres, 
which is sufficiently close for molecular interactions to occur and therefor suitable to 
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investigate physical molecular contacts. The mechanism of FRET involves a donor fluor-
ophore in an excited electronic state that transfers its excitation energy to a nearby ac-
ceptor through dipole-dipole interactions. The occurrence of energy transfer results in 
quenching of donor fluorescence and a reduction of the donor fluorescence lifetime as 
well as an increase in acceptor fluorescence emission. The efficiency of the energy trans-
fer process is strongly dependent on the distance between donor and acceptor mole-
cules making FRET microscopy an ideal tool to investigate direct physical interactions 
(Clegg, 1995). 
For live cell imaging, cells were cultured in 35-mm glass bottom dishes (MatTek). Cells 
were transiently transfected with 0.5 µg 14-3-3_EGFP and 1.5 µg DDR1_mCherry 
(0.5 µg pEGFP-N1 and 1.5 µg pmCherry-N1 as control) using 10 µl Lipofectamine 2000 
according to the manufacturer’s instructions. Cells were incubated at 37 °C and 5 % CO2 
for 4 h. Subsequently, cells were washed with 1x PBS and transfection medium was re-
placed by fresh cell culture medium. Twenty-four hours after transient transfection, live 
cell FRET images were acquired on a confocal microscope (Zeiss 510 LSM) using a C-
Apochromat 63x/1.2 NA water objective. Where indicated, cells were treated with DDR1-
IN-1 (EC50) for 2 h. Image acquisition and analysis of sensitized emission FRET was 
performed as described previously (Jin et al., 2016). For EGFP, mCherry and 14-3-
3_EGFP-to-DDR1_mCherry FRET, fluorophores were excited through an Argon laser at 
488, 514 and 488 nm, respectively. Emission wavelengths were detected with band pass 
filters at 530-580, 580-700 and 580-700 nm, respectively. Corrected FRET intensities 
were calculated from FRET, donor, and acceptor pixel intensities using the Fiji distribu-
tion and the PixFRET plugin (Feige et al., 2005). FRET and normalized FRET (NFRET) 
were collected from the whole cell. 
 
4.2.19 Autophagy analysis 
For Western blot analysis of autophagy induction, cells were seeded on collagen type I 
(1 µg/cm2, BD Biosciences) coated dishes and treated with DDR1-IN-1 (EC50) for 1 h 
prior to 6 Gy X-ray irradiation (DMSO and 0 Gy as control). To determine LC3-II accu-
mulation, 10 nM Bafilomycin A1 was added to the cells at the time of treatment. Cell lysis 
was performed after 24 h incubation at 37 °C and 5 % CO2 and lysates were subjected 
to western blotting. To determine the accumulation of endogenous LC3 positive puncta 
by immunofluorescence, cells were seeded on collagen type I (1 µg/cm2) coated co-
verslips and treated with DDR1-IN-1 (EC50) for 1 h prior to 6 Gy irradiation (DMSO and 
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0 Gy as control). The number of LC3 punctate dots per cell was determined. A minimum 
of 50 cells per sample was counted for triplicate samples per condition per experiment. 
Images were acquired using LSM510meta (Zeiss). 
 
4.2.20 Statistics 
Means +/- s.e.m. of at least three independent experiments were calculated with refer-
ence to controls defined in total numbers or 1.0. For statistical significance analysis of 
clonogenic survival and densitometry, two-sided Student’s t-test was performed using 
Excel (Microsoft). For statistical analysis of animal experiments, an analysis of variance 
(ANOVA) and two-sided log rank test were performed with Prism 7 (GraphPad Software). 
P-values of less than 0.05 are considered statistically significant. For analysis of 
DDR1/Nestin correlation in patient samples, linear regression and calculation of Pearson 
correlation was performed using GraphPad Prism 7 
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5 Results 
5.1 DDR1 Expression in GBM 
5.1.1 DDR1 expression analysis on publicly available data 
As a specific molecular target for personalised cancer therapies, a desired protein of 
interest should meet certain criteria. Mutated protein variants or overexpression in 
Figure 5.1. DDR1 is overexpressed in GBM and conveys poor prognosis. (a) Comparative mRNA ex-
pression analysis of collagen-binding receptors between GBM and normal brain using Oncomine data base
(McLendon et al., 2008) (b) Kaplan Meier survival analysis of GBM patients (right panel: cumulated TCGA 
dataset; left panel: TCGA dataset filtered for chemotherapy treated GBM patients) with low and high DDR1 
expressing tumours. Curves were generated using the TCGA Affymetrix HT HG U133A GBM dataset 
(McLendon et al., 2008) (www.betastasis.com). 
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tumour tissue compared to low or absent expression in normal tissue can offer a suffi-
cient therapeutic window. Additionally, the protein of interest should be involved in tu-
morigenesis and tumour progression and ideally negatively correlate with patient out-
come (Schlag et al., 2007). 
Therapy resistant cell populations critically rely on the cellular and ECM composi-
tion of their local microenvironment. Especially collagen type I was determined as an 
essential factor for GBM stem cell (GSC) homeostasis (Tabatabai et al., 2011; Motegi et 
al., 2014). An Oncomine overexpression analysis on GBM and healthy brain expression 
data from The Cancer Genome Atlas (TCGA) (McLendon et al., 2008) revealed β1 in-
tegrin and DDR1 to be the only overexpressed collagen-binding receptors in GBM 
Figure 5.2. DDR1 expression in GBM cell cultures and patient biopsies. (a) Scheme of DDR1 isoforms 
and primers used for expression analysis. (b) PCR-based expression analysis of DDR1 isoforms in indi-
cated GBM cell cultures. (c) Immunofluorescence images of DDR1 and F-actin stained U343MG, GS-8 and 
DK41 cells. Scale bar, 20 µm. (d) Immunofluorescence images of DDR1 stained GBM patient biopsies. 
Scale bar, 20 µm. 
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(Figure 5.1a). While integrins were already extensively studied and integrin targeting has 
demonstrated low efficacy in clinical trials (Stupp et al., 2014), the role of DDR1 in GBM 
cell survival and therapy resistance remains elusive. Next, the connection between 
DDR1 mRNA expression and overall survival of GBM patients was analysed using 
www.betastasis.org, an analysis tool for GBM data sets of the TCGA. Patients with a 
high DDR1 mRNA expression showed a significantly reduced survival in comparison to 
patients expressing DDR1 in lower amounts (p = 0.013, Figure 5.1b). This tendency was 
even more pronounced when only patients who received chemotherapy with the DNA 
methylating agent Temozolomide (TMZ) were analysed (p = 0.006, Figure 5.1b). To-
gether, these data demonstrate a significant overexpression of DDR1 in GBM compared 
to normal tissue as well as a significant correlation between DDR1 expression and pa-
tient outcome, hence, a potential role for DDR1 as novel molecular target in GBM.  
 
5.1.2 DDR1 expression in GBM cell lines and GBM stem-like cells 
To evaluate the expression of DDR1 isoforms in different GBM cell culture models, spe-
cific primers differentiating between DDR1a-e were generated. The different DDR1 
isoforms were discriminated by size of PCR products generated on either cDNA or ge-
nomic DNA of seven human glioblastoma cell lines (U87MG, A172, LN229, U138MG, 
DD-T4, DD-HT7606, U343MG) and two human glioblastoma stem-like cell cultures (GS-
5, GS-8). While all cell cultures showed expression of the kinase-proficient DDR1 
isoforms a, b and c, none of the cultures expressed the kinase inactive isoforms DDR1d 
and e (Figure 5.2a and b). Moreover, DDR1 showed a membranous as well as cytosolic 
localisation in adherently growing U343MG cells, GS-8 and DK41 GSCs (Figure 5.2c) 
and GBM patient biopsies (Figure 5.2d). On the protein level, the different cell culture 
models displayed varying DDR1 expression with a tendency of higher DDR1 expression 
in the stem-like glioblastoma cultures (Figure 5.3a). In summary, kinase active DDR1 is 
expressed in the whole panel of tested glioblastoma cell cultures, which are therefore 
suitable as model systems to evaluate the effects of DDR1 targeting. 
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5.1.3 The role of DDR1 in GBM stemness 
 A putative connection between DDR1 expression and GBM stemness was investigated 
monitoring the expression of DDR1 and the GBM stemness markers Nestin, Sox-2 and 
Musashi (Bao et al., 2006) as well as the expression of the astrocytic marker GFAP in 
established GBM cell lines and GBM stem-like cells (GSCs). Western blot analysis re-
vealed high levels of GBM stem cell marker expression in GBM cultures expressing high 
levels of DDR1 (Figure 5.3a). This tendency was most pronounced for GSC cultures. 
Moreover, differentiation of GS-8 and DK41 GSC cultures with FBS for 72 h lead to sim-
ultaneous reduction of DDR1, Nestin and Sox-2 expression as well as increased expres-
sion of GFAP (Figure 5.3b-d). These results argue for a potential association of DDR1 
expression and GBM stemness.  
Figure 5.3. DDR1 expression correlates with stem cell marker expression. (a) Western blot analysis 
on whole cell lysates of indicated GBM cell cultures showing DDR1 and GBM stem cell marker expression. 
(b) Representative microscopic images from cells growing in neurobasal medium or DMEM/FBS. Scale bar, 
200 µm. (c) Western blot and (d) densitometric analysis of GS-8 and DK41 cultures before and 72 h after 
differentiation with DMEM supplemented with 10% FBS (n=3, mean ± s.e.m.; two-sided t-test). AU, arbitrary 
units. 
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To validate the determined correlation of DDR1 and GBM stem cell marker expres-
sion, a DDR1/Nestin and DDR1/Sox-2 correlation analysis was performed on a TCGA 
GBM data set (www.betastasis.com). Again, DDR1 mRNA expression showed pro-
nounced correlation with typical GBM stemness markers (DDR1/NES: R2 = 0.49; 
DDR1/SOX2: R2 = 0.59). 
To check for a translational relevance of these findings, 13 biopsy samples of pa-
tients with newly diagnosed GBM were immunohistochemically stained for DDR1 and 
Nestin. Microscopic analysis showed a strong co-localisation of both proteins (Figure 
5.5a). Seventy-two percent of the analysed cells stained positive for DDR1 and 28 % 
showed Nestin expression. Of these cells, 29 % showed DDR1/Nestin double-positivity 
(Figure 5.5b). A subsequent correlation analysis of DDR1 and Nestin expression based 
on mean intensities of DDR1 and Nestin immunohistochemical staining revealed a Pear-
son correlation coefficient between R2 = 0.12 and R = 0.83 for 8 of the 13 biopsies (Fig-
ure 5.5c). Five biopsies showed correlation coefficients between R2 = 0.002-0.02 (Figure 
5.5c). Stratification of patients into groups of high (R2>0.1) and low (R2<0.1) correlation 
of DDR1/Nestin co-expression allowed survival analysis for both groups. Compared to 
patients stratified into the DDR1/Nestin low group with a median overall survival of 
512 ± 169 d, patients showing a high DDR1/Nestin co-expression reported a decreased 
overall survival of 251 ± 177 d (P = 0.08, two-sided t-test, Figure 5.5d). 
Figure 5.4. DDR1 correlates with GBM stem cell marker expression in publicly available patient data. 
Correlation analysis of DDR1, Nestin and Sox-2 expression using the TCGA Affymetrix HT HG U133A GBM 
dataset (McLendon et al., 2008) (www.betastasis.com). 
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Together, these results indicate a connection between DDR1 expression and GBM 
stemness as well as overall patient survival. Hence, the in GBM overexpressed DDR1 
could serve as druggable target to improve GBM patient outcome. 
Figure 5.5. DDR1 and Nestin expression correlate in GBM patient samples. (a) Immunohistochemical 
staining for DDR1 and Nestin in GBM patient biopsies. Scale bar, 20 µm. (b) Percentage of cells stained 
positive for DDR1 and Nestin on sections of paraffin-embedded GBM tumour specimens. (c) Correlation 
analysis of DDR1 and Nestin expression in GBM patient biopsies based on mean intensities of DDR1 and 
Nestin immunohistochemical staining. AU, arbitrary units. (d) Box plot displaying survival of GBM patients 
stratified into groups of high (R2>0.1) and low (R2<0.1) correlation of DDR1/Nestin co-expression. 
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Figure 5.6. DDR1 expression is increased upon X-ray irradiation and DDR1 silencing induces radio-
sensitisation. (a) Western blot analysis and densitometry of DDR1 expression and phosphorylation (Y513) 
on whole cell lysates of indicated GBM cell cultures grown in the absence and presence of Col I without or 
in combination with 6 Gy X-rays. (b) Western blots on whole cell lysates of indicated GBM cell cultures 
showing DDR1 expression upon treatment with specific siRNAs (nonspecific siRNA as control, siC). (c) 
Plating efficiency and (d) clonogenic radiation survival of indicated cell lines upon siRNA-mediated DDR1 
knockdown and 2-6 Gy X-rays (n=3, mean ± s.e.m.; two-sided t-test; *P<0.05; **P<0.01; ***P<0.001). 
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5.2 The role of DDR1 in GBM radiochemoresistance and inva-
sion 
5.2.1 Effect of DDR1 silencing on GBM radiosensitivity 
GBM is typically treated with a multimodal therapy comprising surgery, irradiation and 
chemotherapy with the DNA methylating agent TMZ (Stupp et al., 2005; Stupp et al., 
2009). 
To investigate the role of DDR1 for the cellular radiation response, expression of 
the collagen-binding receptor was evaluated upon X-ray irradiation. Western blot analy-
sis revealed a cell line dependent increase of DDR1 expression and phosphorylation 
following irradiation (Figure 5.6a). Intriguingly, this effect was most pronounced in 
U343MG cells as well as GS-5 and GS-8 GSC cultures expressing high levels of GBM 
stem cell markers suggesting a potential role of DDR1 in response to irradiation.  
Consequently, the role of DDR1 for GBM radioresistance was assessed using 
DDR1-directed small interfering (si)RNAs. In the whole panel of GBM cell lines, DDR1 
silencing resulted in pronounced cytotoxicity at 0 Gy (Figure 5.6b-c) and significantly 
Figure 5.7 DDR1 silencing decreases GBM invasiveness. (a) Representative microscopy images show-
ing cells of indicated cell lines invading a 3D collagen type I matrix upon treatment with DDR1 specific or 
nonspecific siRNA (siC) (t=72 h). Scale bars, 100 µm. (b) Invasion capacity of indicated cell lines in a 3D 
collagen type I matrix monitored over 72 h (n=3, mean ± s.e.m.; two-sided t-test; *P<0.05; **P<0.01; 
***P<0.001). 
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increased radiosensitivity compared to nonspecific control siRNA (Figure 5.6d). To-
gether, these results strongly suggest an impact of DDR1 on GBM radiosensitivity and a 
general role on GBM clonogenicity. 
5.2.2 Effect of DDR1 silencing on GBM invasiveness 
Efficiency of GBM therapy is not only limited by resistance to radio- and chemotherapy, 
but also indefinable borders of glioblastoma cell infiltration into the surrounding healthy 
tissue making total resection impossible (Vehlow and Cordes, 2013). This infiltration in 
the brain parenchyma occurs mainly along blood vessels with the vessel-associated col-
lagens type I and IV playing a major role for GBM invasion (Payne and Huang, 2013). 
As both collagens are DDR1 ligands necessary for its activation (Vogel et al., 1997), the 
effect of DDR1 depletion on the invasion capacity of GBM cells in a 3D collagen type I 
matrix was evaluated.  
GBM cells were allowed to form spheroids prior to transfer into 3D collagen type I 
matrix and cell invasion out of the spheroid into the surrounding matrix was monitored. 
In general, the invasion capacity varied substantially within the panel of tested GBM cell 
lines (Figure 5.7a-b). DDR1-depleted GBM cells showed a highly significant average 
decrease in invasion distance of 37.3 ± 8.3 %. The greatest effect of DDR1 silencing on 
invasiveness was detected in A172, where the invasion distance was reduced by 
61.2 ± 14.2 % (Figure 5.7b). These results suggest an involvement of DDR1 in GBM 
invasiveness. Hence, two important drivers of gliomagenesis are controlled by DDR1 
rendering DDR1 a potent molecular target in GBM. 
 
5.2.3 Pharmacological inhibition of DDR1 in vitro 
Since DDR1 was found to impact on GBM radioresistance and invasiveness, a more 
translational DDR1 targeting approach was performed using the pharmacological inhib-
itor DDR1-IN-1 (DDR1i). DDR1i EC50 concentrations were sufficient to reduce DDR1 
phosphorylation in a time dependent manner (Figure 5.8c). Next, the effect of DDR1i 
treatment on basal and clonogenic radiation survival as well as glio-sphere formation 
capacity (0-6 Gy) was tested. A significant reduction of basal survival as well as radio-
sensitisation of U343MG cells and GSC cultures was determined (Figure 5.9a-b). This 
effect was comparable to the effect of siRNA mediated depletion of DDR1 arguing for 
the specificity of the inhibitor treatment (Figure 5.6c-d).  
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Additionally, the efficacy of a DDR1 single targeting was compared to either sole 
TMZ treatment or a combined DDR1i/TMZ regimen using EC10 and EC50 concentrations 
for either substance (Figure 5.8a-b). In clear contrast to inhibition of DDR1, sole TMZ 
treatment resulted in significant reduction of basal cell survival but did not radiosensitise 
the tested GBM cultures (Figure 5.9c-d). On the contrary, for DK41 and DK42 GSC cul-
tures a radioprotective effect of TMZ was noted (Figure 5.9c-d).  
DDR1i/TMZ co-administration resulted in increased cytotoxicity at basal conditions 
(Figure 5.9e) and superior radiosensitisation compared to the single treatment ap-
proaches (Figure 5.9f). While the combined treatment showed additive effects on radio-
sensitivity in GSC cultures, a synergic effect of DDR1i and TMZ was determined for 
U343MG cells (Table 5.1). Importantly, the combinatorial DDR1i/TMZ treatment lead to 
radiosensitisation in DK41 and DK42 cultures that were initially radioprotected by sole 
TMZ treatment (Figure 5.9f). Taken together, these results strongly argue for the poten-
tial of DDR1 targeting to overcome GBM radio- and chemoresistance in vitro. 
  
Figure 5.8. Pharmacological inhibition of DDR1. (a) TMZ and DDR1i cytotoxicity and (b) corresponding 
EC10 and EC50 values of U343MG cells (colony formation assay) and GSC cultures (sphere assay) (n=3). 
(c) Western blot on whole cell lysates showing a time-dependent DDR1 dephosphorylation upon DDR1i 
treatment (n=3). 
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Table 5.1. Synergistic and additive effects of combined DDR1i/TMZ treatment. Synergistic and addi-
tive effects were calculated using the formula published by (Yan et al., 2010). Formula: S = r(a, b) – r(a0, 
b) x r(a, b0). a = DDR1i; b = TMZ. Synergistic effects are shown in red. Additive effects are shown in blue.  
 
r(a, b) r(a0, b) r(a, b0) S 
U343MG 
0 Gy 
2 Gy 
4 Gy 
6 Gy 
 
0.0616667 
0.0116667 
0.0011111 
0.0000000 
 
0.0938889 
0.0236111 
0.0047222 
0.0004861 
 
0.1119444 
0.0327778 
0.0055556 
0.0008333 
 
0.0511563 
0.0108927 
0.0010849 
-0.0000004 
GS-5 
0 Gy 
2 Gy 
4 Gy 
6 Gy 
 
0.00308 
0.00183 
0.00158 
0.00083 
 
0.00375 
0.00233 
0.00200 
0.00150 
 
0.00333 
0.00258 
0.00225 
0.00175 
 
0.00307 
0.00183 
0.00158 
0.00083 
GS-8 
0 Gy 
2 Gy 
4 Gy 
6 Gy 
 
0.01283 
0.00800 
0.00633 
0.00358 
 
0.01725 
0.01250 
0.00875 
0.00633 
 
0.01925 
0.01358 
0.01042 
0.00817 
 
0.01250 
0.00783 
0.00624 
0.00353 
DK32 
0 Gy 
2 Gy 
4 Gy 
6 Gy 
 
0.01133 
0.00625 
0.00300 
0.00150 
 
0.01958 
0.01342 
0.00950 
0.00608 
 
0.01408 
0.01142 
0.00708 
0.00583 
 
0.01106 
0.00610 
0.00293 
0.00146 
DK41 
0 Gy 
2 Gy 
4 Gy 
6 Gy 
 
0.04542 
0.03817 
0.02933 
0.01233 
 
0.05583 
0.03875 
0.01983 
0.01108 
 
0.06892 
0.06383 
0.04792 
0.02800 
 
0.04157 
0.03569 
0.02838 
0.01202 
DK42 
0 Gy 
2 Gy 
4 Gy 
6 Gy 
 
0.00583 
0.00458 
0.00342 
0.00150 
 
0.00833 
0.00467 
0.00375 
0.00167 
 
0.00800 
0.00500 
0.00475 
0.00383 
 
0.00577 
0.00456 
0.00340 
0.00149 
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Figure 5.9. Radiation survival upon DDR1i, TMZ and combined DDR1i/TMZ treatment. (a) Basal and 
(b) clonogenic radiation survival of indicated cells treated with DDR1i without or in combination with 2-6 Gy 
X-rays. (c) Basal and (d) clonogenic radiation survival of indicated cells treated with TMZ without or in 
combination with 2-6 Gy X-rays. (e) Basal and (f) clonogenic radiation survival of indicated cells treated 
concomitantly with TMZ and DDR1i without or in combination with 2-6 Gy X-rays (DMSO as control, n=3, 
mean ± s.e.m.; two-sided t-test; *P<0.05; **P<0.01; ***P<0.001). 
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5.2.4 DDR1 inhibition in an orthotopic GBM mouse model 
Genetic and pharmacological inhibition of DDR1 significantly radio- and chemosensitised 
GBM cells in vitro. Consequently, a prove-of principle animal study in an orthotopic GBM 
mouse model was performed.  
Seven days after tumour cell transplantation, mice were randomly assigned into 3 
treatment groups, treated in accordance to the treatment schedule presented in Figure 
5.10a-b and monitored for tumour growth twice weekly with the IVIS system upon injec-
tion of D-luciferin (Figure 5.10c). While DDR1i single treatment had no significant effect 
on tumour growth and overall survival compared to the 0.9 % NaCl control, the combi-
nation of DDR1i to X-ray irradiation resulted in a significant delay of tumour growth (Fig-
ure 5.10d-e). Moreover, the DDR1i/RT regimen extended the median overall survival 
from 32.5 d for the control group to 37 d (Figure 5.10e). Concomitant treatment with 
DDR1i, TMZ and irradiation significantly delayed tumour growth and prolonged median 
survival from 29 d (0.9 % NaCl) over 34 d (TMZ + RT) to 41 d (DDR1i + TMZ + RT) (Fig-
ure 5.10d, e, g), while combining TMZ to X-ray irradiation failed to exceed the effects of 
sole radiotherapy (Figure 5.10d, e, g). Of note, 3 out of 11 animals of the DDR1i/TMZ/RT 
treatment arm survived for more than 180 d, which was the maximal observation time.  
These results clearly indicate the benefits of combining DDR1 inhibition to the cur-
rently used standard treatment regimen of TMZ + radiotherapy to radiosensitise GBM 
cells, reduce tumour growth and prolong overall survival. 
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Figure 5.10. DDR1 targeting in a GBM mouse model. (a) Immunohistochemical images of orthotopic GS-
8_GFP/fLuc tumours. N, necrosis. V, blood vessel. Arrows, invasive GBM cells. Scale bars H&E, 500 µm. 
Scale bar IHC, 20 µm. (b) Treatment scheme. Mice received 0.9% NaCl (CTL), TMZ (22 mg/kg) and/or 
DDR1i (25 mg/kg) and 4 Gy X-rays on three consecutive days. (c) Representative luminescence images of 
tumour bearing mice upon indicated treatments. (d) tumour growth (mean ± s.e.m.) and (e) calculated tu-
mour growth delay in mice bearing orthotopic GS-8_GFP/fLuc tumours treated with DDR1i (25 mg/kg) and 
TMZ (22 mg/kg). Mice were irradiated with 4 Gy 3 h after drug injections. Treatment was repeated on 3 
consecutive days. (f and g) Kaplan Meier survival curves of DDR1i (25 mg/kg) and/or TMZ (22 mg/kg) 
treated mice bearing orthotopic GS-8_GFP/fLuc tumours. Mice were irradiated with 4 Gy 3 h after drug 
injections. Treatment was repeated on 3 consecutive days. *P<0.05; **P<0.01; ***P<0.001; two-sided log 
rank test. 
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Figure 5.11. DDR1 signalling via Akt/mTOR. (a) Phosphoproteome analysis of 342 proteins and 606 
phospho-sites (Full Moon Biosystems) on whole cell lysates of DDR1i treated U343MG cells. Relative phos-
phorylation changes of all regulated proteins are shown. Data are presented as fold change to DMSO con-
trol after normalisation to total protein expression. (b) Overrepresentation analysis of regulated proteins 
identified by phosphoproteome analysis following DDR1i treatment of U343MG cells (geneonthology.org). 
(c) Relative phosphorylation changes of proteins associated with Akt/mTOR signalling upon DDR1i treat-
ment. (d) DDR1 regulated proteins mapped on Akt/mTOR interactome based on phosphoproteome data. 
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5.3 DDR1 signalling in GBM 
5.3.1 Akt/mTOR signalling axis 
Due to its potential to overcome GBM radiochemoresistance for improved patient sur-
vival, DDR1 targeting offers the opportunity to be applied as novel targeting strategy for 
personalised medicine. Hence, the investigation of the signalling mechanisms underlying 
the treatment effects is of great interest. To define mechanisms underlying the enhanced 
sensitivity to radiation elicited by DDR1 targeting, broad-spectrum phosphoproteome 
analysis investigating 606 phospho-sites from over 30 signalling pathways on whole cell 
Figure 5.12. Akt and mTOR dephosphorylation upon DDR1 inhibition. (a) Western blots and (b) den-
sitometric analysis on whole cell lysates of U343MG, GS-8 and DK41 cells as well as orthotopic GBM tu-
mour homogenates showing phosphorylation changes upon DDR1i treatment (mean ± s.e.m.; two-sided t-
test). 
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lysates of U343MG cells was applied. The phosphoproteome analysis revealed 30 pro-
teins with enhanced phosphorylation (≥ 50 %) and 48 proteins reporting a reduced phos-
phorylation (≤ 30 %) including GBM drivers like PTEN, Akt and PDGFR (Figure 5.11a). 
A bioinformatic overrepresentation analysis on different cancer-relevant pathways (PAN-
THER pathways on www.geneonthology.org revealed that, among other GBM related 
pathways like FGFR, EGFR, PDGRF and VEGFR signalling, the phosphatidylinositol 3-
kinase-Akt-mechanistic target of rapamycin (PI3K-Akt-mTOR) signalling pathway 
showed the highest degree of overrepresentation within the phosphoproteom data set 
Figure 5.13. Radiosensitisation by DDR1 inhibition involves Akt/mTOR signalling. (a) Western blots 
on whole cell lysates showing knockdown efficiency of Akt1, DDR1 and combined knockdown. (b and c) 
Plating efficiency and clonogenic radiation survival upon (b) Akt1 or (c) combined DDR1/Akt1 depletion 
without and in combination with 2-6 Gy X-rays. (d) Western blots on whole cell lysates showing the knock-
down efficiency of single and simultaneous knockdown of Raptor, Rictor and DDR1. (e and f) Plating effi-
ciency and clonogenic radiation survival upon (e) Raptor, Rictor and (f) combined DDR1/Raptor, DDR1/Ric-
tor siRNA knockdown without and in combination with 2-6 Gy X-rays (nonspecific siRNA as control (siC), 
mean ± s.e.m., two-sided t-test, *P<0.05; **P<0.01; ***P<0.001. 
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(Figure 5.11b). Thirty-seven percent of the proteins assigned to the PI3K-Akt-mTOR 
pathway by the KEGG database (www.kegg.jp) were found to be regulated upon DDR1 
inhibition (Figure 5.11c, d). Subsequently, the effects of DDR1 targeting on Akt/ mTOR 
signalling revealed by the phosphoproteome array were confirmed by western blotting 
on whole cell lysates of U343MG cells as well as GS-8 and DK41 GSC cultures (Figure 
5.12). Most important, this effect could be confirmed in homogenates of orthotopic GBM 
tumours treated with DDR1i (Figure 5.12).  
Based on these results, Akt1 as well as the mTOR subunits Raptor and Rictor were 
depleted to comparatively investigate the single targeting effects on GBM basal and clon-
ogenic radiation survival. Single Akt1 as well as Raptor and Rictor knockdown resulted 
in cytotoxicity and radiosensitisation of U343MG cells. However, this effect was found to 
be less potent than sole DDR1 depletion (Figure 5.13a, b and d, e). Simultaneous 
DDR1/Akt1, DDR1/Raptor/Rictor and single DDR1 depletion, were found to be equally 
effective in terms of cytotoxicity and radiosensitisation (Figure 5.13c, f). This argues for 
a signalling axis jointly used by DDR1, Akt and mTOR to regulate GBM cell survival upon 
radiation-induced genotoxic injury. 
Since DDR1 and Akt or Raptor/Rictor seemed to signal via a jointly used signalling 
axis, co-immunoprecipitations on whole cell lysates of U343MG and GS-8 cells were 
Figure 5.14. DDR1 co-precipitates with Akt1. Co-immunoprecipitation of DDR1 and Akt1 with endoge-
nous DDR1 on whole cell lysate of U343MG and GS-8 cells (IgG as control). 
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employed to investigate whether direct interaction of the three proteins could link DDR1 
to Akt/ mTOR signalling. While neither Raptor nor Rictor co-precipitated with DDR1, Akt1 
was found in DDR1 precipitates (Figure 5.14).  
These findings emphasise the existence of a physical connection of DDR1 to the Akt/ 
mTOR axis that is potentially disrupted upon DDR1 inhibition leading to reduced Akt/ 
mTOR phosphorylation and radiochemosensitivity. 
 
5.3.2 14-3-3/Beclin-1/Akt1 protein complex 
To test whether Akt1 physically interacts with DDR1, an analysis of putative Akt1 binding 
motifs in DDR1 was performed using the GPS kinase prediction tool (Xue et al., 2005; 
Xue et al., 2008). Intriguingly, DDR1 did not contain Akt1 binding sites suggesting Akt1 
to bind DDR1 via a multiprotein complex. To investigate proteins physically bound to 
DDR1 and potentially facilitating the linkage between DDR1 and Akt1, mass spectrome-
try on DDR1 immunoprecipitates was performed. Mass spectrometry analysis detected 
a total 58 specifically DDR1 bound proteins (Table 5.2). Gene ontology analysis (Huang 
et al., 2009) revealed an accumulation of proteins regulating translation, cell-cell adhe-
sion, apoptosis and mTOR signalling (Figure 5.15a). Most important, 14-3-3 theta, a part 
of the Akt/mTOR axis and dephosphorylated after DDR1 inhibition (Figure 5.11b), was 
found among the DDR1 bound proteins.  
Figure 5.15. Mass spectrometry detects a DDR1 bound 14-3-3/Beclin-1/Akt1 complex. (a) Functional 
annotation clustering (DAVID gene onthology (Huang et al., 2009)) of DDR1 bound proteins detected by 
mass spectrometry following DDR1 immunoprecipitation (IgG as control). (b and c) Immunoprecipitation of 
a DDR1/14-3-3/Beclin-1/Akt1 complex with endogenous DDR1, 14-3-3 and Beclin-1 on whole cell lysate of 
(b) U343MG and (c) GS-8 (IgG as control). 
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Table 5.2. DDR1 bound proteins detected by mass spectrometry following DDR1 immunoprecipitation (IgG 
as control). 
Protein Hits Molecular weight 
 
IgG DDR1  
MAP4 0 82 121 kDa 
LARP1 0 30 129 kDa 
GOLGA1 0 22 88 kDa 
HSPB1 0 19 23 kDa 
DHX30 0 14 128 kDa 
RRBP1 0 11 109 kDa 
KTN1 0 8 156 kDa 
RPL4 0 6 53 kDa 
WRNIP1 0 11 72 kDa 
CAST 0 7 80 kDa 
RPL3 0 6 49 kDa 
NCOA1 0 6 149 kDa 
TRIM24 0 8 113 kDa 
UBAP2L 0 9 115 kDa 
SCRIB 0 4 178 kDa 
NUP214 0 5 218 kDa 
EIF3A 0 7 97 kDa 
CRYAB 0 7 20 kDa 
SRRM2 0 3 300 kDa 
RPS16 0 5 16 kDa 
LUC7L2 0 4 47 kDa 
C14orf166 0 5 29 kDa 
ATF7IP 0 5 107 kDa 
VIM 0 5 50 kDa 
DDR1 0 3 101 kDa 
RPL23A 0 3 18 kDa 
FAM120C 0 4 121 kDa 
SEC31A 0 4 122 kDa 
FNBP4 0 4 90 kDa 
MATR3 0 3 95 kDa 
SCYL2 0 3 104 kDa 
YWHAQ 0 5 28 kDa 
DOCK7 0 3 241 kDa 
PDE4DIP 0 3 261 kDa 
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HNRNPC 0 3 34 kDa 
RPS6 0 3 29 kDa 
SRSF10 0 2 34 kDa 
RPS27L 0 2 9 kDa 
RPL31 0 2 15 kDa 
VARS 0 2 140 kDa 
FMR1 0 5 74 kDa 
ARHGEF11 0 3 172 kDa 
ATXN2 0 3 124 kDa 
KCTD3 0 3 89 kDa 
PRRC2A 0 2 229 kDa 
EIF3C 0 2 69 kDa 
TRIM28 0 2 76 kDa 
EIF3E 0 2 52 kDa 
LRRC15 0 2 64 kDa 
AP2B1 0 2 104 kDa 
ZC3H7A 0 2 84 kDa 
RPL23 0 2 14 kDa 
DDX3Y 0 17 73 kDa 
PCBP2 0 2 38 kDa 
STRAP 0 2 38 kDa 
PURB 0 2 33 kDa 
RBM3 0 2 17 kDa 
DNAJA3 0 2 49 kDa 
 
Recently, an autophagy regulating 14-3-3/Beclin-1/Vimentin complex was de-
scribed to be mediated by Akt phosphorylation (Wang et al., 2012). To investigate po-
tential physical interactions between DDR1, 14-3-3, Beclin-1 and Akt1, immunoprecipi-
tations on whole cell lysates of U343MG and GS-8 were performed. Collectively, DDR1, 
14-3-3 and Beclin-1 immunoprecipitations proved interaction between these proteins 
(Figure 5.15b, c) suggesting 14-3-3/Beclin-1Akt1 complex assembly on DDR1 and a joint 
function in DDR1 signalling.  
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To identify the direct physical link between DDR1 and the 14-3-3/Beclin-1/Akt1 
complex, immunofluorescence staining and Fluorescence Resonance Energy Transfer 
(FRET) microscopy were used. Immunofluorescence analysis showed co-localisation of 
DDR1 and 14-3-3 at the cell membrane, which was disrupted upon DDR1 inhibition (Fig-
ure 5.16). For FRET analysis, HT7606 and HEK293T cells were transiently transfected 
with DDR1_mCherry and 14-3-3_EGFP (Figure 5.17a). Direct physical interactions were 
detected in both cell lines (Figure 5.17b). When DDR1 was inhibited, a time dependent 
decrease of 14-3-3-to-DDR1 FRET intensity as well as FRET count was observed (Fig-
ure 5.17b-d).   Together   these   results   argue  for  a  direct   physical   protein-protein 
Figure 5.16. DDR1 inhibition leads to disassembly of the DDR1/14-3-3 complex. (a) Representative 
immunofluorescence images and (b) expression profiles of endogenous DDR1 and 14-3-3 in HT7606 cells 
showing DDR1 and 14-3-3 co-localisation and complex disassembly upon DDR1i treatment. Arrows indicate 
sites of co-localisation. Scale bar, 5 µm. 
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Figure 5.17. Detection of 14-3-3-to-DDR1 FRET. (a) Confocal microscopy of cells expressing indicated 
fluorescent fusion proteins in HT7606 GBM and HEK293T cells. Scale bars, 10 µm. (b) Confocal micros-
copy of HEK293T cells expressing fluorescent fusion proteins 14-3-3_EGFP and DDR1_mCherry. Repre-
sentative images of sensitised emission FRET and normalised FRET (NFRET) analysis before and upon 
DDR1 inhibition. Three-dimensional plot of NFRET intensities shows decreasing 14-3-3-to-DDR1 FRET 
upon DDR1 inhibition. Scale bars, 10 μm. (c and d) Sensitised emission FRET analysis of 14-3-3/DDR1 
interaction showing (c) NFRET intensity and detected count and (d) normalized maximal NFRET intensity 
before (0 h), during and 24 h after exposure to DDR1i. 
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interaction between DDR1 and 14-3-3 that is disrupted upon DDR1 inhibition. 
Next, kinase prediction algorithms (Xue et al., 2005; Xue et al., 2008) indicated two 
putative 14-3-3 binding sites (R-X-X-S448 and R-X-X-S889) in the intracellular jux-
tamembrane and kinase domain of DDR1 (Figure 5.18a). These motifs resemble 14-3-3 
protein binding sites as well as a putative Akt phosphorylation consensus (Wang et al., 
2012). 
To further show the importance of DDR1/14-3-3 complex assembly for the effects 
of DDR1 inhibition on radiochemosensitivity, DDR1 GST-fusion proteins of the wildtype 
receptor (DDR1WT), variants with intracellular deletions (DDR1ΔKD, DDR1ΔICD) and 
point mutated variants (DDR1S448A, DDR1S889A, DDR1AA) preventing phosphoryla-
tion at the putative 14-3-3 binding sites (Figure 5.18b) were constructed. While pulldown 
of DDR1WT-GST showed binding of the 14-3-3/Beclin-1/Akt1 complex, 14-3-3, Beclin-1 
and Akt1 were unable to bind to deletion and mutated DDR1 variants (Figure 5.18c). In 
line with these results, pharmacological inhibition of DDR1 induced disruption of the en-
dogenous protein complex (Figure 5.18d). Together these results demonstrate direct 
binding of 14-3-3 to DDR1 at two distinct protein binding motifs connecting DDR1 to the 
autophagy and apoptosis regulators Beclin-1 and Akt1.  
Figure 5.18. 14-3-3 directly binds to DDR1 to facilitate linkage to Akt/mTOR signalling. (a) Alignment 
of conserved sequences of DDR1 predicts 14-3-3 binding motifs. (b) Scheme of DDR1 deletion and muta-
tion variants used for functional analysis. (c) Pulldown of indicated DDR1-GST fusion constructs from 
HEK293T whole cell lysate. (d) Co-immunoprecipitation of endogenous DDR1, 14-3-3, Beclin-1 and Akt1 
from GS-8 whole cell lysates upon DDR1i treatment. 
    Results 
85 
 
5.4 The role of DDR1 inhibition in autophagy 
To discriminate between DDR1 function in apoptosis and autophagy, caspase 3, 8 and 
9 cleavage were analysed. Upon DDR1 inhibition, no significant increase in cleaved 
caspases compared to the control was detected (Figure 5.19). However, Beclin-1 disso-
ciated form DDR1 upon DDR1i treatment suggesting a role of this complex in regulation 
of autophagy, a fundamental cellular process frequently hijacked by cancer cells in re-
sponse to therapeutic treatment (Galluzzi et al., 2016). Beclin-1 binding to BCL-2 and 
BCL-xL controls vesicle nucleation during the early steps of the autophagic process, 
thus, preventing formation of the multiprotein autophagy-core-complex (Pattingre et al., 
2005; Fulda and Kögel, 2015) built by Beclin-1 binding to Vps34 and ATG14 (Zhong et 
al., 2009). To test for a critical role of DDR1 in autophagy, Beclin-1 immunoprecipitation 
Figure 5.19. DDR1 inhibition does not induce apoptosis. (a) Western blot and (b) densitometric analysis 
of caspase 3, 8 and 9 cleavage upon DDR1i treatment and 6 Gy X-rays at indicated time points on whole 
cell lysate of U343MG cells (n=3, mean ± s.e.m., two-sided t-test). 
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upon DDR1 inhibition was employed. Upon DDR1i treatment Beclin-1 dissociated from  
DDR1 to form a complex with Vps34 and ATG14 (Figure 5.20). This suggested autoph-
agy induction via assembly of the Beclin-1/Vps34/ATG14 autophagy core complex 
(Zhong et al., 2009; Russell et al., 2013; Fulda and Kögel, 2015). In line with this finding, 
an increased number of LC3 positive autophagosomes and enhanced accumulation of 
lipidated LC3 (LC3-II) was observed upon Bafilomycin A1 (Baf A1) and DDR1i treatment 
in U343MG, GS-8 and DK41 cells (Figure 5.21). Baf A1 is an inhibitor of the late phase 
of autophagy, applied to discriminate between autophagy induction and blockade 
(Klionsky et al., 2008; Mizushima et al., 2010). Autophagy induction was even more pro-
nounced when DDR1i treatment was combined with 6 Gy X-ray irradiation (Figure 5.21a-
b and d-e). Detection of increased LC3-I-to-LC3-II conversion in homogenates of 
Figure 5.20. Beclin-1 dissociates from DDR1 upon DDR1 inhibition. (a) Co-Immunoprecipitation and 
(b) densitometric analysis of endogenous Beclin-1 with DDR1, ATG14 and Vps34 on whole cell lysate of 
U343MG and GS-8 cells upon DDR1i treatment. Data are mean ± s.e.m., comparison by two-sided t-test. 
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orthotopic GBM tumours treated with DDR1i confirmed these observations (Figure 5.21c 
and f). 
To prove that DDR1i induction of autophagy is causative for cell death and 
radiosensitisation, Beclin-1 depleted U343MG cells were treated with DDR1i for 1h and 
subsequently subsequently irradiated with 6 Gy X-rays. As expected, cells treated with 
nonspecific siRNA displayed reduced survival upon DDR1 inhibition and IR when 
Figure 5.21. DDR1 inhibition induces autophagy. (a) Immunofluorescence images showing LC3 puncta 
(green) and nuclei (DAPI, blue) and (d) analysis of LC3 puncta formation upon exposure to DDR1i and 6 
Gy X-rays (n=3; for each condition 50 cells per replicate were counted). Scale bars, 10 µm. (b and c) West-
ern blots and (e and f) densitometric analysis showing LC3-II accumulation in Baf-A1 treated cells and LC3-
I to LC3-II conversion in homogenates of orthotopic GBM tumours upon DDR1 inhibition relative to corre-
sponding controls (n=3). 
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compared to DMSO treated controls (Figure 5.22a). In contrast, DDR1i treatment in 
U343MG cells deficient for Beclin-1 did not lead to radiosensitisation (Figure 5.22a). 
Together these results argue for the induction of cytotoxic autophagy upon DDR1 
inhibition finally resulting in cell death following IR.  
To confirm disassembly of the DDR1/14-3-3/Beclin-1/Akt1 complex and the role of 
Beclin-1 as an essential mediator of autophagy upon DDR1 inhibition, U343MG cells 
were transiently transfected with the different DDR1-GST deletion and mutant variants. 
Compared to empty-vector controls, DDR1WT-GST expression resulted in reduced ac-
cumulation of LC3-II, in line with reduced sensitivity to ionising radiation (Figure 5.22b 
and c). Expression of the deletion constructs or mutated variants with a defective 
DDR1/14-3-3/Beclin-1/Akt1 complex formation restored autophagy and lead to radiosen-
sitisation (Figure 5.22b and c). These results show that activated DDR1 directly interacts 
with 14-3-3, Beclin-1 and Akt1 to promote GBM cell therapy resistance by preventing 
autophagy induction. 
  
Figure 5.22. Autophagy induction accounts for the effects of DDR1 inhibition. (a) Clonogenic radiation 
survival of Beclin-1 depleted U343MG cell cultures treated with DDR1i and 6 Gy X-rays. (b) Western blots 
and densitometry showing an LC3-II accumulation and (c) clonogenic radiation survival (6 Gy) of U343MG 
cells transiently transfected with indicated DDR1 constructs. Data are mean ± s.e.m., comparison by two-
sided t-test. 
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6 Discussion 
GBM remains a tumour type with great unmet need. Despite multimodal therapy comprised of 
maximal safe surgery, radiotherapy and chemotherapy with TMZ as well as advances in the 
optimisation of treatment schedules and the identification of prognostic markers such as 
MGMT, less than 5% of patients diagnosed with a glioblastoma survive more than 5 years 
(Becker and Yu, 2012). In terms of treatment efficacy, resistance to therapy remains a big 
challenge for the successful treatment and cure of cancer patients. Besides resistance devel-
opment mediated by growth factor receptors (Razis et al., 2009; Garraway and Jänne, 2012; 
Holohan et al., 2013; Stuhlmiller et al., 2015), cell-ECM interactions have been shown to es-
sentially contribute to cancer radiation and drug resistance (Cordes et al., 2003; Sandfort et 
al., 2007; Nam et al., 2010; Storch et al., 2010; Eke et al., 2015; Seguin et al., 2015). Especially 
integrins have been found to be essential mediators of cell-adhesion mediated drug- and radi-
oresistance (Cordes and Meineke, 2005). Similar to integrins, the receptor tyrosine kinase 
DDR1 binds to and is activated by collagens. In various tumour entities, including lung and 
pancreatic cancer, a role of DDR1 in tumour development, progression and therapy resistance 
has been suggested (Couvelard et al., 2006; Rikova et al., 2007). In GBM, however, a direct 
link to therapy resistance has not been established (Vogel et al., 1997; Leitinger, 2014). As 
intrinsic and acquired resistances to anticancer treatment represent universal clinical chal-
lenges (Garraway and Jänne, 2012; Holohan et al., 2013), the unravelling of underlying cellular 
and microenvironment-driven mechanisms remain of fundamental importance. Consequently, 
this study aimed at the identification of the role of DDR1 for GBM radiochemoresistance and 
invasiveness as well as the detection of the underlying signalling mechanisms. 
By considering cell-ECM interactions as key drivers of resistance, we show here that (i) 
DDR1 is overexpressed in GBM, (ii) co-expression of the promitotic and adhesion-mediating 
receptor tyrosine kinase DDR1 with GBM stem cell markers in clinical samples correlates with 
patient outcome, (iii) inhibition of DDR1 enhances sensitivity and prolongs survival in response 
to radiochemotherapy with Temozolomide compared to conventional therapy in vitro and in 
vivo, (iv) induces autophagy via regulation of the Akt/mTOR signalling axis, which (v) is 
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mediated by a DDR1 bound 14-3-3/Beclin-1/Akt1 protein complex that is required for prosur-
vival Akt/mTOR signalling and regulation of autophagy. 
 
6.1 DDR1 expression correlates with GBM stemness and conveys 
radiochemoresistance and invasiveness 
Prior studies in colorectal, breast and lung cancer implicate that DDR1 is overexpressed rela-
tive to corresponding normal tissues and promotes resistance mechanisms indicating its po-
tential as cancer target (Ongusaha et al., 2003; Rikova et al., 2007). The comparative expres-
sion analysis of collagen-binding proteins conducted in this study revealed an overexpression 
of only two receptors, i.e. β1 integrin and DDR1. As β1 integrin single-targeting was already 
proven ineffective and to induce treatment circumventing bypass signalling via JNK in in vitro 
and in vivo GBM models (Vehlow et al., 2017) and the αvβ3/β5 integrin-antagonist Cilengitide 
failed to improve outcome in a phase III clinical trial in GBM patients (Stupp et al., 2014), this 
study, consequently, focused on DDR1. Underpinning the potential role of DDR1 for GBM 
therapy response, also two important DDR1 ligands, collagen type I and IV, were found to be 
overexpressed. Collagens have been described to populate CSC niches, thereby shaping an 
environment where tumour cells survive treatment and propagate into recurrence (Payne and 
Huang, 2013; Motegi et al., 2014). In line, this study found DDR1 expression to correlate with 
the expression of the GBM stemness marker Nestin and, importantly, patient survival in an 
analysis of GBM patient samples. These observations confirm previous studies that suggested 
a relationship between DDR1 expression and patient survival and attributed prognostic and 
predictive value to DDR1 (Yamanaka et al., 2006). Furthermore, a study on subpopulations of 
GBM initiating cells reported DDR1 as potential biomarker for GBM stemness (Rennert et al., 
2016) and Gao and colleagues found DDR1 to guide homing of metastasised breast cancer 
stem-like cells by establishing a niche at distant organs via activation of collagen I secretion 
(Gao et al., 2016). The overexpression of DDR1 in GBM and its connection to GBM stemness 
and patient survival proved the potential of DDR1 as novel target for GBM therapy. Moreover, 
this observation seems of utmost importance for the clinic where patients receive multimodal 
therapy for eradicating bulk and stem-like GBM cell populations. 
DDR1 targeting, indeed, elicited tumour cell death and prolonged overall survival in dif-
ferent in vitro and in vivo cancer models. In a study on KRAS-mutant lung cancer, Ambrogio 
and co-workers identified DDR1 as the most important mediator of Kras signalling (Ambrogio 
et al., 2016). Genetical and pharmacological inhibition of DDR1 with the DDR1 targeting com-
pound 7rh effectively repressed tumour growth in a KRAS/TP53-mutant patient-derived lung 
xenografts (PDX) with a therapeutic efficacy comparable to standard chemotherapy. Similar 
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observations were obtained in an orthotopic mouse model of pancreatic adenocarcinoma 
(PDAC) where 7rh-mediated DDR1 inhibition resulted in reduced tumour burden, chemosen-
sitisation and, in combination with gemcitabine and nab-paclitaxel, an significantly prolonged 
overall survival (Aguilera et al., 2017). The present study confirms these observations in DDR1-
overexpressing GBM showing DDR1 targeting as effective approach to radiochemosensitise 
GBM cells in vivo and in vitro. While most DDR1 targeting studies solely focus on DDR1 single-
targeting or combinations with other experimental targeting approaches, this study documents 
the added value of DDR1 targeting on top of radiochemotherapy and showed that DDR1 inhi-
bition is potent to radiochemosensitise and prolong the survival of orthotopic GBM tumour 
bearing mice. These findings pinpoint the translatability of this targeting strategy. Based on the 
feasibility of this proof-of-concept study with high efficacy and low toxicity, further supportive 
translational investigations in other GBM models are warranted to finally achieve reasonable 
and safe translation into the clinic. 
DDR1 targeting did not only impact on GBM cell survival but also reduced the invasive-
ness of GBM cells in collagen type I gels. These findings corroborate data from a previous 
study in GBM that attributed a potential invasion-promoting role to DDR1 (Ram et al., 2006). 
Ram and colleagues used DDR1a and DDR1b overexpressing G140 GBM cells to shown in-
creased cell adhesion on DDR1 substrates and enhanced cell migration performing a chemo-
taxis-based transwell assay. In contrast to Ram et al., this study tested the inherent invasion 
capability of GBM cell lines and GSC cultures in more physiological 3D collagen type I gels. A 
role of DDR1 in invasion and migration was further postulated in various other tumour entities. 
A study in MDA-MB-231 breast cancer and A549 lung cancer cells identified DDR1 as driver 
of linear invadosome formation on collagen type I matrices. Short hairpin RNA (shRNA)-medi-
ated depletion of DDR1 resulted in decreased formation of linear invadosomes, matrix restruc-
turing and tumour cell invasion in a Cdc42/Tuba dependent manner (Juin et al., 2014). Hidalgo-
Carcedo et al. showed DDR1 depletion to block collective invasion in a range of two-dimen-
sional, three-dimensional and organotypic breast cancer models (Hidalgo-Carcedo et al., 
2010). Moreover, a study applying shRNA-mediated DDR1 depletion in a mouse model for 
lung cancer-to-bone metastasis found DDR1 to fundamentally impact on cell survival, homing 
and colonisation in lung cancer bone metastasis (Valencia et al., 2012). 
In summary, these data establish DDR1 as important driver of GBM radiochemo-
resistance and invasion, two features essentially contributing to GBM pathology.  
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6.2 DDR1 inhibition impacts on Akt/mTOR signalling 
Despite first hints on how DDR1 contributes to GBM pathogenesis and resistance, the under-
lying mechanisms are still unsolved. Hence, a broad spectrum phosphoproteome analysis was 
performed upon DDR1 inhibition to untangle DDR1-mediated signal transduction eliciting radi-
ochemosenstisation. In addition to modifications in the phosphorylation of well-known GBM 
drivers like PTEN, EGFR and PDGFR (Verhaak et al., 2010), a prominent downregulation of 
the Akt/mTOR axis was detected. Constitutive activation of the Akt/mTOR axis with the sub-
sequent amplification of prosurvival signals and blockage of tumour suppressor proteins is 
found in the majority of glioblastomas (Wei et al., 2013). In line, an increased activity of the 
PI3K repressive protein PTEN, downregulation of Akt phosphorylation as well as reduced 
phosphorylation of mTOR and its downstream effector protein P70S6Kβ were detected upon 
DDR1 inhibition. Together with the results of the Akt/DDR1, Raptor/DDR1 and Rictor/DDR1 
double knockdown experiments showing similar radiosensitising effects as sole DDR1 knock-
down, these data argue for a pathway jointly used by DDR1, Akt and mTOR and emphasise a 
major role for DDR1 in GBM pathology.  
These results are in agreement with previous studies reporting regulation of Akt/mTOR 
signalling by DDR1. In a study on breast cancer cells, Matà and colleagues found induced 
DDR1 expression upon IGF-I stimulation, which was accompanied by enhanced PI3K/Akt sig-
nalling finally leading to stimulation of proliferation and cancer-cell migration (Matà et al., 2016). 
In contrast to the findings of this study, DDR1 was shown to negatively regulate the Akt path-
way in nasopharyngeal carcinoma cells (Lu et al., 2016).  
In GBM, Hambardzumyan and co-workers found radioresistant, Nestin positive CSCs to 
activate PI3K/Akt signalling for survival upon irradiation and blockage of the Akt signalling axis 
by Perifosine to result in treatment sensitisation and radiation-induced apoptosis in tumour 
bearing mice (Hambardzumyan et al., 2008). Similarly, studies on GSC cultures reported in-
duced phosphorylation of Akt upon irradiation. Pharmacological inhibition of the Akt/mTOR 
axis lead to radiosensitisation, activation of DNAPK mediated DNA repair and enhanced irra-
diation-induced DNA damage (Kang et al., 2012; Mehta et al., 2015). Consistently, Yoon et al. 
reported Akt inhibition to suppress the formation and self-renewal of sphere-cultured GBM 
cells. Moreover, disruption of the Akt cascade by the PI3K/Akt inhibitor LY294002 specifically 
reduced the population of CD133/Nestin positive cells in patient-derived primary GBM cultures 
(Yoon et al., 2012). Further evidence for the specificity of Akt inhibition to eradicate 
CD133/Nestin positive GSCs is reported by two independent research groups that found re-
duced neurosphere formation, induction of apoptosis and impairment of GBM invasion upon 
Akt inhibition (Daniele et al., 2015; Miao et al., 2015). 
Consistent with these studies connecting enhanced activity of the Akt/mTOR cascade in 
GBM with tumour progression and stemness-promoting functions, the findings of the present 
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study suggest great advantages of DDR1 targeting induced repression of Akt/mTOR signalling 
in GBM.  
 
6.3 A 14-3-3/Beclin-1/Akt1 complex physically connects DDR1 to 
the Akt/mTOR axis 
To determine direct DDR1 binding partners and to further connect to Akt/mTOR signalling, 
mass spectrometry on DDR1 immunoprecipitates was performed. Consistent with the results 
of the phosphoproteome analysis not only proteins involved in translation initiation like eIF-3A, 
eIF-3C and eIF-3E or in cell movement like ARHGEF11, HspB1 or Vimentin, but also various 
candidates of the Akt/mTOR pathway such as LARP1 and RPS6 were found in DDR1 immuno-
precipitates. Most intriguingly, 14-3-3τ was found to be bound to DDR1 and dephosphorylated 
upon DDR1 inhibition. 14-3-3 proteins are adapter molecules that function in a variety of cel-
lular processes by mediating protein-protein interactions. 14-3-3 proteins directly bind phos-
phorylated Serine or Threonine residues for assembly with a multitude of functionally diverse 
molecules including kinases, phosphatases, transmembrane receptors, cytoskeletal proteins 
and transcription factors (Zhao et al., 2011). Binding of 14-3-3 proteins to target proteins is 
thought to affect protein localisation, conformation, stability and activity (Kaplan et al., 2017). 
As 14-3-3 proteins are involved in numerous signalling pathways that control diverse physio-
logical and pathological processes, dysregulation of 14-3-3-to-target interactions have been 
show to fundamentally contribute to human diseases including cancer (Kaplan et al., 2017). 
Different 14-3-3 isoforms including 14-3-3β, ζ and τ, have been shown to be overexpressed in 
cancer and to regulate various oncogenic signalling pathways as well as chemosensitivity 
(Zhao et al., 2011). However, detailed molecular mechanisms by which each isoform of the 
14-3-3 family contributes to tumorigenesis and resistance to therapy are lacking.  
This study adds on the existing knowledge about the role of 14-3-3 proteins in cancer by 
describing a DDR1 bound 14-3-3/Beclin-1/Akt1 complex that connects DDR1 to the Akt/mTOR 
pathway and is required for GBM prosurvival signalling. Importantly, DDR1 contains the 14-3-
3 binding motif R-X-X-S in its intracellular juxtamembrane and kinase domains. FRET analysis 
and exogenous expression of variants with mutations in the putative 14-3-3 binding sites 
proved direct binding and dependence of DDR1 regulated Akt/mTOR signalling on complex 
assembly. These findings are in line with several studies reporting a critical role of 14-3-3 pro-
teins for regulation of the Akt/mTOR axis. In cancer cells, Beclin-1, an essential autophagy and 
tumour suppressor protein, was found to be phosphorylated by Akt in a 14-3-3/Beclin-1/Vi-
mentin complex (Wang et al., 2012). Akt-mediated phosphorylation of Beclin-1 enhanced its 
interactions with 14-3-3 and Vimentin intermediate filament proteins and was necessary for 
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regulation of autophagy. Using breast and lung cancer cells, Jeon and colleagues identified 
14-3-3 as negative regulator of the mTORC2/Akt pathway (Jeon et al., 2013). Reduced inter-
action between Rictor, a component of mTORC2, and 14-3-3 in the presence of Selenoprotein 
W led to reduced Akt phosphorylation and rendered cells more sensitive to DNA damage in-
duced by etoposide. Similarly, in a study on PDAC, 14-3-3 was found to mediate interaction of 
GSK3β, a downstream effector protein of Akt, with the transcription factor EB (TFEB) for reg-
ulation of cancer cell survival via stimulation of autophagy (Marchand et al., 2015). 
Together, these findings establish DDR1 as direct binding partner of 14-3-3τ and further 
connect DDR1 to the prosurvival Akt/mTOR axis via description of a yet unknown receptor-
bound14-3-3/Beclin-1/Akt1 complex. Moreover, in combination with its regulatory role on 
Akt/mTOR signalling, the engagement of DDR1 with the well-known autophagy-mediating pro-
teins 14-3-3 and Beclin-1 suggest a central role for DDR1 in autophagy regulation. 
 
6.4 DDR1 inhibition induces autophagy for radiochemosensitisa-
tion 
As 14-3-3τ was reported to regulate autophagy via modification of Akt phosphorylation (Wang 
et al., 2012) and DDR1 inhibition failed to induce apoptosis, regulation of autophagy through 
the newly uncovered DDR1/14-3-3/Beclin-1/Akt1 complex seemed possible. Autophagy can 
act as a tumour-suppressing mechanism. The impairment of autophagy resulting in a lack of 
proper removal of toxic protein aggregates and organelles such as dysfunctional mitochondria 
has been shown to promote oxidative stress, DNA lesions and genomic instability. Hence, 
stimulation of autophagy upon genotoxic injury has been proposed to be a cellular resistance 
mechanism counteracting therapeutic intervention (Gozuacik and Kimchi, 2004; Fulda and 
Kögel, 2015). Studies in favour of this theory reported an induction of survival-mediating au-
tophagy in GBM cell lines suppressing the antitumour effect of TMZ (Kanzawa et al., 2004). 
The use of 3-MA (class III PI3K inhibitor) or bafilomycin A1 restored TMZ cytotoxicity suggest-
ing autophagy inhibition in combination with TMZ could improve TMZ cytotoxicity and reduce 
tumour cell survival (Zou et al., 2014). In line, Dolma and co-workers found the dopamine 
receptor D4 antagonists PNU 96145E and L-741,742 to selectively inhibited GSC growth by 
suppression of PDGFRβ, ERK1/2, and mTOR signalling. Impairment of these pathways led to 
disruption the autophagy-lysosomal pathway, G0/G1 arrest and apoptosis (Dolma et al., 2016). 
Moreover, in a study combining the Akt inhibitor MK-2206 with the EGFR inhibitor gefitinib in 
GBM cell lines, Cheng et al. reported inhibition of autophagy by silencing of Beclin-1 or 3-MA 
treatment to increase the cytotoxicity of the combinatorial treatment. Hence, autophagy 
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induced by MK-2206 and gefitinib were suggested to play a cytoprotective role in this context 
(Cheng et al., 2012). 
In clear contrast to the current paradigm that autophagy counteracts anticancer treat-
ment, this study detected induction of a cytotoxic variant of autophagy, termed autophagic cell 
death (Fulda and Kögel, 2015; Galluzzi et al., 2016), upon DDR1 inhibition. These findings are 
in line with accumulating evidence from preclinical and clinical studies pointing to enforced 
over-activation of autophagy as an effective approach for autophagy-induced cell death. More-
over, these studies emphasise the importance of the context in which investigations of autoph-
agy are performed and highlight the dual role of autophagy as tumour-suppressing and cell 
death-stimulating mechanism (Fulda and Kögel, 2015; Galluzzi et al., 2016). Confirming the 
findings of this study, Voss and colleagues found the pan-Bcl-2 inhibitor (−)-gossypol in com-
bination with TMZ to efficiently induce cell death in a panel of GBM cell lines. The effects of 
the combined treatment were abrogated upon knockdown of Beclin-1 or Atg5 indicating that 
autophagy contributed to treatment elicited cell death (Voss et al., 2010). A study using the 
kinase inhibitor dasatinib found decreased phosphorylation of Src, AKT and RPS6 levels which 
resulted in a significant increase in autophagic cell death (Milano et al., 2009). As dasatinib 
also reduces DDR1 phosphorylation in addition to the Src/Akt axis, the findings underline the 
potential of DDR1 inhibition to induce autophagy for cell killing. Moreover, this study described 
a combinatorial dasatinib/TMZ treatment approach to even increase the level of autophagy-
driven cell death in GBM cell lines. In agreement with these findings, Kuwahara et al. reported 
reduced autophagic flux in a panel of radioresistant cancer cell lines compared to their radio-
sensitive counterparts (Kuwahara et al., 2011). Reduced autophagy induction upon irradiation 
resulted in enhanced proliferation of the radioresistant cells and impairment of autophagy ren-
dered radiosensitive cells insusceptible to X-rays.  
Further, the findings of the current study are in line with the results of autophagy-inhibit-
ing agents like chloroquine or hydroxychloroquine in clinical trials. In general, trials testing 
these agents have mostly demonstrated negligible efficacy, thus questioning the therapeutic 
potential of autophagy-inhibiting treatments. When used in combination with dose-intensive 
temozolomide-based chemotherapy, hydroxychloroquine induced only three partial responses 
and six instances of disease stabilisation in a cohort of 40 patients with advanced-stage solid 
tumours including GBM (Rangwala et al., 2014). Similarly, in a study on 92 with newly diag-
nosed glioblastoma patients treatment with hydroxychloroquine in combination with radiother-
apy plus adjuvant TMZ had no significant effect on patient survival compared to the irradia-
tion/TMZ control group (Rosenfeld et al., 2014). Hence, new strategies to allow autophagy to 
occur for therapy sensitisation are required as currently available clinical data do not support 
the hypothesis that pharmacological inhibition of autophagy enhances the clinical efficacy of 
anticancer therapies. Such an approach might be highly potent to augment the effectiveness 
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of radiochemotherapy (Voss et al., 2010; Ladoire et al., 2015; Yang et al., 2015; Dou et al., 
2016). This assumption is in line with the strategy presented in this study. 
 
 
In summary, this study reveals an important role of DDR1 for GBM cell survival and invasion 
as it presents genetic and pharmacological DDR1 targeting strategies as highly effective, es-
pecially when combined with TMZ and irradiation. Furthermore, the study links the resistance-
mediating receptor tyrosine kinase DDR1 to GBM stemness and reveals a correlation between 
high DDR1 expression and patient survival. Mechanistically, the results presented here provide 
evidence for prosurvival and resistance-mediating signalling via a DDR1/14-3-3/Beclin-1/Akt1 
pathway underscoring DDR1 targeting as attractive approach in combination with radio- and 
chemotherapy for patients suffering from GBM. The radiochemosensitising effects of DDR1 
inhibition resulted in induction of autophagic cell death for tumour cell eradication. Moreover, 
these findings point at the potential of autophagy-inducing therapies as current strategies aim-
ing at autophagy inhibition for treatment sensitisation failed in clinical trials. These data pro-
pose DDR1 as potential cancer target providing a rationale for combinatorial therapies with 
novel targeting agents administered as adjuvants to conventional radiochemotherapy for highly 
therapy-refractory cancers such as GBM. 
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7 Summary 
Background: Glioblastomas (GBM) are characterised by genetic and epigenetic alterations in 
resistance-mediating genes and destructive infiltration of the surrounding normal brain. Cell 
adhesion molecules play an important role for intrinsic and acquired therapy resistances. 
Among the group of adhesion molecules, the collagen-binding discoidin domain receptor 1 
(DDR1) is considered as potential, druggabale and promising cancer target owing to its own 
tyrosine kinase activity and its overexpression in various cancer types. This study evaluates 
the so far unknown role of DDR1 in GBM invasion and response to radiochemotherapy and 
investigates the underlying molecular mechanisms. 
Materials and Methods: Expression of DDR1 and GBM stem cell markers was evaluated in 
13 biopsies of patients with primary GBM and correlated with overall survival. The effects of 
DDR1 inhibition by either DDR1-siRNA or DDR1 inhibitor (DDR1-IN-1), Temozolomide (TMZ) 
or a DDR1-IN-1/TMZ combination on GBM invasion capacity and cancer cell survival upon 
irradiation were evaluated in a panel of 7 GBM cell lines, 5 GBM stem-like cell cultures and an 
orthotopic GBM mouse model. Changes in underlying signal transduction mechanisms after 
DDR1 inhibition were assessed by Western blot and broad-spectrum phosphoproteome anal-
ysis. Direct DDR1 binding partners were evaluated by immunoprecipitation, mass spectrome-
try, FRET analysis, truncated and mutated DDR1 variants and GST-pulldown. 
Results: DDR1 was found to be co-expressed with GBM stem cell markers in clinical GBM 
samples. High DDR1/Nestin co-localisation correlated with poor patient outcome. In GBM 
models a pharmacological DDR1 inhibition enhanced sensitivity and prolonged survival in re-
sponse to radiochemotherapy with Temozolomide compared to conventional therapy. Moreo-
ver, a 50 % reduced invasion was determined in GBM cell cultures. Mechanistically, DDR1 
inhibition impaired Akt/mTOR signalling and induced LC3b protein expression and formation 
of LC3b-positive autophagosomes suggesting autophagy for GBM radiochemosensitisation. 
Further, mass spectrometry on DDR1 immunoprecipitates identified a 14-3-3/Beclin-1/Akt1 
protein complex as linker to the prosurvival Akt-mTOR axis. FRET analysis and GST-pulldown 
of truncated DDR1 variants identified complex assembly at DDR1 to be required for prosurvival 
Akt/mTOR signalling, regulation of autophagy and radichemosensitisation. 
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Conclusion: These data suggest DDR1 targeting in GBM to be highly effective for radi-
ochemosensitisation via autophagy induction, impairment of cell invasion and superior to the 
current conventional therapy. Based on its overexpression and key function in prosurvival 
mechanisms, targeting of the druggable DDR1 provides a rationale for combinatorial therapies 
with novel adjuvant autophagy-inducing agents administered with conventional radiochemo-
therapy. 
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8 Zusammenfassung 
Hintergrund: Das Glioblastom (GBM) zeichnet sich durch genetische und epigenetische Ver-
änderungen in resistenzvermittelnden Genen sowie starke Infiltration gesundem Hirngewebes 
aus. Zelladhäsionsmoleküle spielen bezüglich intrinsischer und erworbener Therapieresisten-
zen eine entscheidende Rolle. Aufgrund seiner eigenen Kinaseaktivität sowie seiner Überex-
pression in verschiedenen Tumorentitäten eignet sich der Kollagen-bindende Discoidin Do-
main Rezeptor 1 (DDR1) als vielversprechendes Zielmolekül für die Krebstherapie. Die vorlie-
gende Arbeit untersucht den bisher unbekannten Einfluss von DDR1 auf die Invasionsfähigkeit 
von Glioblastomzellen und deren zelluläre Antwort auf Radiochemotherapie sowie die zugrun-
deliegenden molekularen Mechanismen.  
Material und Methoden: Die Expression von DDR1 und GBM Stammzellmarkern wurde in 13 
Biopsien von Patienten mit primärem GBM untersucht und mit dem Patientenüberleben korre-
liert. Die Effekte einer DDR1 Hemmung mit DDR1-siRNA oder einem DDR1 Inhibitor (DDR1-
IN-1), Temozolomide (TMZ) oder einer DDR1-IN-1/TMZ Kombination auf die Invasionsfähig-
keit von GBM Zellen und das Zellüberleben nach Bestrahlung wurden in 7 GBM Zelllinien, 5 
primären GBM Kulturen und einem orthotopen GBM Mausmodell untersucht. Veränderungen 
in den DDR1 beeinflussten Signalkaskaden wurden mittels Western Blot und Phosphoproteo-
manalyse ermittelt. Direkte DDR1 Interaktionspartner wurden mit Hilfe von Immunpräzipitatio-
nen, Massenspektrometrie, FRET Analysen, verkürzten und mutierten DDR1 Varianten sowie 
GST-pulldown Analysen ermittelt.  
Ergebnisse: In den untersuchten Patientenbiopsien wurde eine Ko-Expression von DDR1 mit 
GBM Stammzellmarkern festgestellt, die negativ mit dem Patientenüberleben korrelierte. Nach 
DDR1 Hemmung wurde eine gesteigerte Sensibilität gegenüber einer durchgeführten Radio-
chemotherapie mit Temozolomide sowie ein verbessertes Gesamtüberleben im GBM Maus-
modell festgestellt. Weiterhin reduzierte die Hemmung von DDR1 die Invasionsfähigkeit von 
GBM Zellen um durchschnittlich 50%. Nach Inhibierung von DDR1 wurde eine reduzierte 
Phosphorylierung von verschiedenen Proteinen der Akt/mTOR Signalkaskade und eine Induk-
tion der LC3b Expression sowie LC3b-II positiver Autophagosomen festgestellt. Des Weiteren 
wurde mittels Massenspektrometrie nach DDR1 Immunpräzipitation ein 14-3-3/Beclin-1/Akt1 
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Komplex als Bindeglied zwischen Rezeptor und dem resistenzvermittelnden Akt/mTOR Sig-
nalweg ermittelt. Mittels FRET Analyse und GST-pulldown modifizierter DDR1 Konstrukte 
wurde die Assemblierung des identifizierten Komplexes an DDR1 als grundlegender Mecha-
nismus für überlebensfördernde Signale via Akt/mTOR, die Regulation von Autophagie und 
die Vermittlung von Radiochemoresistenz im GBM entschlüsselt. 
Schlussfolgerung: Diese Daten zeigen, dass die Hemmung von DDR1 GBM Zellen effektiv 
über Induktion von Autophagie radiochemosensibilisiert, GBM Invasion reduziert und dabei 
potenter ist, als die momentane Standardbehandlung aus Temozolomide und Bestrahlung. 
Basierend auf der Überexpression von DDR1 im Glioblastom und seiner entscheidenden Rolle 
für das Überleben von GBM Zellen bietet eine gezielte Hemmung von DDR1 die Möglichkeit 
einer neuen Behandlungsstrategie in Kombination mit konventioneller Radiochemotherapie.  
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